# REFERENCES


AABB (2021) Biotherapies: www.aabb.org/news-resources/resources/cellular-therapies [3/1/2024].

Abbot, S., Agbanyo, F., Ahlfors, J.-E., Baghbaderani, B. A., Bartido, S. et al. (2018) Report of the international conference on manufacturing and testing of pluripotent stem cells, *Biologicals*, 56: 67–83.

Abbott, A. (2013) Stem-cell ruling riles researchers, *Nature*, 495: 418–419.

Abbott, K. W., Levi-Faur, D., and Snidal, D. (2017) Introducing regulatory intermediaries, *The Annals of the American Academy*, 670: 6–13.

Abertay University (2021) Research reveals UK stem cell clinics using misleading marketing techniques: www.abertay.ac.uk/news/2021/research-reveals-uk-stem-cell-clinics-using-misleading-marketing-techniques/ [3/1/2024].

Abraham, J. (2002) Regulatory science as culture: Contested two-dimensional values at the US FDA, *Science as Culture*, 11(3): 309–335.

Absolute Health (2013) Absolute Health. Regenerative Clinic: https://absolute-health.org/en/?SID=gv5kfkuhj41b6oiqupbb11bgp0 [3/1/2024].

Accesswire (2014) Japan's bold initiative in regenerative medicine and who the big winners might be. 3 March: http://bit.ly/48gmtzK [3/1/2024].

Adams, R. (2000) Loving mimesis and Girard's 'scapegoat of the text': A creative reassessment of mimetic desire. In W. Swartley (ed.) *Violence Renounced: René Girard, Biblical Studies, and Peacemaking*. Telford, PA: Pandora Press US, 277–307: https://web.archive.org/web/20090327074008/http://web.ustpaul.uottawa.ca/covr2006/Document/RebeccaGirard.pdf [3/1/2024].

Alcoff, L. M. (2006) *Visible Identities: Race, Gender and the Self*. New York: Oxford University Press.

AMED (2017) AMED: Overseas Offices: www.amed.go.jp/en/aboutus/overseas.html [03/01/2024].

American Academy of Orthopaedic Surgeons (2016) Benefits of stem cells for treating spinal cord injuries assessed: www.sciencedaily.com/releases/2016/04/160429105533.htm.

AMMS (2014) AMMS: www.stemcellscurediabetes.com/The-Academy-of-Military-Medical-Sciences-of-the-PLA-(AMMS).html [05/01/19].




Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Anderson, M., and McCleary, K. K. (2016) On the path to a science of patient input, *Science Translational Medicine*, 8(336): 11.

Angell, M. (1997) The ethics of clinical research in the Third World, *New England Journal of Medicine*, 337(12): 847–849.

Anonymous (2010) Wild East or scientific feast, *The Economist*, 14 January: www.economist.com/science-and-technology/2010/01/14/the-end-of-an-institution [22/1/2024].

(2015) Stem the tide: Japan has introduced an unproven system to make patients pay for clinical trials, *Nature*, 528(7581): 163–164.

(2021) Scientists raise alarm as Italian government rules on unproven stem cell therapy, *EuroStemCell*: www.eurostemcell.org/scientists-raise-alarm-italian-government-rules-unproven-stem-cell-therapy [3/1/2024].

Anspach, M. (2017) *Vengeance in Revenge*. East Lansing: Michigan State University.

Arendt, H. (1970) *On Violence*. Orlando: Harcourt.

ARM (2016) Homepage: http://alliancerm.org [3/1/2024].

ASCI (2022) Asian Stem Cell Institute: https://asianstemcellinstitute.com/ [3/1/2024].

Athersys (2013) Athersys' multistem(R) stem cell therapy receives orphan drug designation in Europe for prevention of graft-versus-host disease: https://bit.ly/48DSstt [3/1/2024].

(2016) Healios and Athersys enter into regenerative medicine partnership for treatment of stroke using MultiStem(R) Therapy (press release). 8 January: www.athersys.com/investors/press-releases/press-release-details/2016/Healios-and-Athersys-Enter-Into-Regenerative-Medicine-Partnership-for-Treatment-of-Stroke-Using-MultiStemR-Therapy/default.aspx [3/1/2024].

Ausbiotech (2021) Ausbiotech: www.ausbiotech.org/about-us/regenerative-medicine-advisory-group [3/1/2024].

Azuma, K. (2015) Regulatory landscape of RM in Japan, *Current Stem Cell Report*, 1: 118–128.

Azuma, M., and Yamanaka, S. (2016) Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies, *Regenerative Therapy*, 4 (2016): 36e47.

Baldwin, R., and Black, J. (2007) Really responsive regulation. LSE Law, Society and Economy Working Papers 15/2007. London School of Economics: Law Department.

Batt, S. (2017) *Health Advocacy Inc.: How Pharmaceutical Funding Changed the Breast Cancer Movement*. Vancouver: University of British Columbia Press.

B&D (2014) PLA Navy General Hospital: www.stemcellshealthcare.com/about-us/pla-navy-general-hospital [3/1/2024].

Barry, A. (2006) Technological zones, *European Journal of Social Theory*, 9(2): 239–253.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Basu, S. (2012) Making a difference: A mother's courage, *The Hindu*, 29 February: www.thehindu.com/life-and-style/society/article2945835.ece [3/1/2024].

Begon, M., Harper, J. L., and Townsend, C. R. (2006) *Ecology: Individuals, Populations and Communities. From Individuals to Ecosystems*. Malden; Oxford; Victoria: Blackwell Science.

BeikeBiotech (2010) Beike Biotech and Premier Wen Jiabao. 12 October: www.youtube.com/watch?v=V8Lgz27EtbE [3/1/2024].

(2014) Chinese researchers find stem cells effective in treating Systemic Lupus Erythematosus: https://beikebiotech.com/blog/2014/06/26/chinese-researchers-find-stem-cells-effective-in-treating-systemic-lupus-erythematosus/ [3/1/2024].

(2016a) Quality: https://beikebiotech.com/quality/ [3/1/2024].

(2016b) Beike History: https://beikebiotech.com/beike-history/ [3/1/2024].

(2016c) Partnerships: https://beikebiotech.com/partnerships/ [3/1/2024].

(2021a) Stem cell therapy for other conditions: https://stemcell treatmentnow.com/treatments/general/ [3/1/2024].

(2021b) Testimonials: https://stemcelltreatmentnow.com/testimonials/ [3/1/2024].

Bell, C. (2009) *Ritual, Ritual Theory, Ritual Practice*. Oxford: Oxford University Press.

Bharadwaj, A., and Glasner, P. (2008) *Local Cells, Global Science: The Rise of Embryonic Stem Cell Research in India*. London; New York: Routledge.

Bharadwaj, A. (2012) Enculturating cells: The anthropology, substance, and science of stem cells, *Annual Review of Anthropology*, 41: 303–317.

(2013) Ethic of consensibility, subaltern ethicality: The clinical application of embryonic stem cells in India, *BioSocieties*, 8: 25–40.

(2013) Subaltern biology? Local biologies, Indian odysseys and the pursuit of human embryonic stem cell therapies, *Medical Anthropology*, 32(4): 359–373.

(2018) *Global Perspectives on Stem Cell Technologies*. Basingstoke: Palgrave Macmillan.

Bianco, P. (2013) Don't market stem-cell products ahead of proof, *Nature*, 499: 255.

Bianco P., Cao X., Frenette P. S., Mao J. J., Robey P. G. et al. (2013a) The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine, *Nature Medicine*, 19: 35–42.

Bianco, P., Barker, R., Brüstle, O., Cattaneo, E., Clevers., et al. (2013b) Regulation of stem cell therapies under attack in Europe: For whom the bell tolls, *EMBO Journal*, 32: 1489–1495.

(2014) 'Mesenchymal' stem cells, *Annual Review of Cell Developmental Biology*, 30: 677–704.

Bianco, P., and Sipp, D. (2014) Sell help not hope, *Nature*, 510, 336–337.

Bioeconomy Corporation (2014) Press Release: www.bioeconomycorporation.my/bionexus-status-companies-poised-for-solid-growth-with-a-record-of-rm4-4-billion-investments-since-inception/ [3/3/2015].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Bionet (2007) Information Paper. The right mix of biology, metaphysics and culture: stem cell research in Europe and China, LSE: www.lse.ac.uk/researchAndExpertise/units/BIONET/pdfs/BIONET_Info_Paper1_Stem_Cell_Research.pdf [3/1/2024].

Bionews Texas (2013) News Release: http://bionews-tx.com/news/2013/03/05/wattanosoth-cancer-hospital-held-the-first-cancer-tumor-board-teleconference-with-the-university-of-texas-md-anderson-cancer-center/Biotechcorp [6/2/2020].

Bipartisan Policy (2016) Bipartisan REGROW Act would advance regenerative cell therapy. Bipartisan Policy Center news release. March 17: https://regmedfoundation.org/2016/03/17/bipartisan-regrow-act-would-advance-regenerative-cell-therapy/ [3/1/2024].

Birch, K. (2012) Knowledge, place, and power: Geographies of value in the bioeconomy, *New Genetics and Society,* 31(2), 183–201.

Black, J. (2002) Critical reflections on regulation, *Australian Journal of Legal Philosophy* 1, 25.

(2005) Proceduralisation and polycentric regulation, *Revista Direito GV,* Especial: www.academia.edu/72462700/Proceduralisation_and_polycentric_regulation [3/1/2024].

(2021) Constitutionalising regulatory governance systems (March 27), *LSE Legal Studies Working Paper*, No. 02/2021: https://ssrn.com/abstract=3813812 or http://dx.doi.org/10.2139/ssrn.3813812 [3/1/2024].

Blanc, Y., and Bessière, M. (2001) Mark Anspach: Global markets anonymous victims, *The Courier, UNESCO*: www.markanspach.com/short-reads/anonymous-victims/ [3/1/2024].

Blasimme, A., and Rial-Sebbag E. (2012) Regulation of cell-based therapies in Europe: Current challenges and emerging issues, *Stem Cells Dev.*, 22 (Suppl. 1): 14–19.

BMJ (2023) Too much medicine: www.bmj.com/too-much-medicine [3/1/2024].

Boland, L. K., Burand, A. J., Boyt, D. T., Dobroski, H., Di, L., Liszewski, J. N., Schrodt, M. V., Frazer, M. K., Santillan D. A., Ankrum, J. A. (2019) Nature vs. nurture: Defining the effects of mesenchymal stromal cell isolation and culture conditions on resiliency to palmitate challenge, *Frontiers in Immunology*, 10: https://doi.org/10.3389/fimmu.2019.01080 [3/1/2024].

Braithwaite J. (2008), *Regulatory Capitalism: How It Works, Ideas for Making It Work Better.* Cheltenham, UK; Northampton, MA: Edward Elgar.

Brown, C. (2012) Stem cell tourism poses risk, *CMAJ*, 184(2): E121–E122.

Brown, N. (2003) Hope against hype: Accountability in biopasts, presents and futures, *Science and Technology Studies,* 16(2): 3–21.

(2019) *Immunitary Life: A Biopolitics of Immunity*. Basingstoke: Palgrave Macmillan.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Brown, N., and Michael, M. (2003) An analysis of changing expectations: Or 'retrospecting prospects and prospecting retrospects', *Technology Analysis and Strategic Management*, 15: 3–18.

Bufacchi, V. (2005) Two concepts of violence, *Political Studies Review*, 3(2): 193–204.

(2007) *Violence and Social Justice*. Basingstoke: Palgrave Macmillan

Busch, L. (2000) *The Eclipse of Morality. Science, State, and Market.* New York: Aldine de Gruyter

(2011) *Standards. Recipes for Reality.* Cambridge, MA: MIT Press.

Calvert, M. J., Marston, E., Samuels, M., Cruz Rivera, S., Torlinska, B., et al. (2021) Advancing UK regulatory science and innovation in healthcare, *Journal of the Royal Society of Medicine*, 114(1): 5–11.

Cambrosio, A., Keating, P., Schlich, T., and Weisz, G. (2006) Regulatory objectivity and the generation and management of evidence in medicine, *Social Science & Medicine*, 63(1): 189–199.

Cancer Hospital Wattanosoth (2024) Bangkok Hospital HQ's Bangkok Cancer Hospital Wattanosoth and Be Well Medical Center enter into strategic collaboration: www.wattanosothcancerhospital.com/en/news-events/be-well-medical-center-x-bangkok-cancer-hospital-wattanosoth [3/1/2024].

Canguilhem, G. (1989) *The Normal and Pathological.* Cambridge, MA; London: MIT Press.

Castells, M. (2000) *The Rise of the Network Society: The Information Age: Economy, Society, and Culture*. New York: John Wiley.

Caulfield, T., and Murdoch, B. (2019) Regulatory and policy tools to address unproven stem cell interventions in Canada: The need for action, *BMC Med Ethics*, 20: 51.

Carpenter, D. (2010) *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA*. Princeton: Princeton University Press.

CBMG (2015) Cellular Biomedical Group, Inc. Securities and Exchange Commission Edgar Filing. 31 March: www.annualreports.com/HostedData/AnnualReportArchive/c/NASDAQ_CBMG_2014.pdf [3/1/2024].

CDSCO (Central Drugs Standard Control Organisation) (2013) Guidance Document for Regulatory Approvals of Stem Cell and Cell Based Products (SCCPs) SCCPs/SPS/2013-001, Version: 004. December 30: www.scribd.com/document/215468898/Guidance-Document-for-Regulatory-Approvals-of-Stem-Cell-and-Cell-Based-Products-SCCPs [3/1/2024].

CDB (2016) How foreign non-profit organisations should respond to China's new Overseas NGO Management Law: http://chinadevelopmentbrief.cn/articles/how-foreign-non-profit-organisations-should-respond-to-chinas-new-overseas-ngo-management-law/ [3/1/2024].

CDPF (2016) China's Disabled Persons' Federation: www.cdpf.org.cn/english/ [5/1/19].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

CDPF (2021) 3-sided cooperation between the Civil Affairs Bureau, the China Disabled Persons' Federation and the Inclusion Factory: https://inclusion-factory.com/en/3761.html [3/1/2024].

CellPort (2022) CellPort International. Stem cell augmentation: www.facebook.com/CellportTH/ [3/1/2024].

Centre for Sustainable Healthcare (2020) Green social prescribing for sustainable healthcare: https://sustainablehealthcare.org.uk/what-we-do/connecting-q-locally/green-social-prescribing-sustainable-healthcare [3/1/2024].

CFDA (2015) 关于印发干细胞临床研究管理办法（试行）的通知 [Guanyu Yinfa ganxibao linchuang yanjiu guanli banfa (shixing) de tongzhi; Administrative Measures for Clinical Research of Stem Cells (for Trial Implementation)], NHFPC. 21 August: www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=28635ef99c5743e294f45e8b29c72309 [3/1/2024].

Chaisinthop, N. (2014) 'Cell therapy' in Thailand: Negotiating space, legitimacy, ambiguity and alliances. Paper presented at the *Biannual Workshop of the Centre for Bionetworking*, University of Sussex. 7 July.

Chan, S., and Harris, J., (2009) Free riders and pious sons: Why scientific research remains obligatory, *Bioethics*, 23(3): 161–171.

Chen H. (2017) Reflection on the governance of clinical stem cell research and applications in China, *Regenerative Medicine,* 12(6): 593–597.

Chen, H., and Gottweis, H. (2013) Stem cell treatments in China: Rethinking the patient role in the global bio-economy, *Bioethics*, 27(4):194–207.

Chen, Y.-C., Cheng, H.-F., and Yeh, M.-K. (2017) Cell therapy regulation in Taiwan, *Cell Transplantation*, 26: 483–492: www.ncbi.nlm.nih.gov/pmc/articles/PMC5657697/ [3/1/2024].

China Daily (2016) Alliance for stem cell technologies established in Guangzhou: www.chinadaily.com.cn/china/2016-03/29/content_24169162.htm [3/1/2024].

ChinaSCInet (2020) Clinical trials in ChinaSCINet: www.chinascinet.org/index.php?option=com_content&task=view&id=106&lang=en [2/12/2020].

Chinese Academy of Science (2013) China to further regulate stem cell clinical experiments, 8 March, CAS: https://english.cas.cn/newsroom/archive/china_archive/cn2013/201303/t20130308_99433.shtml [3/1/2024].

Choosing Wisely UK (2023) About Choosing Wisely UK: https://choosingwisely.co.uk/about-choosing-wisely-uk/ [3/1/2024].

Chulalongkorn University (2013) HRH Princess Maha Chakri Sirindhorn presided over grand opening for robotic stem cell processing laboratory at Faculty of Medicine. 8 October: www.chula.ac.th/en/archive/681 [l2/6/2015].

CiRA (2012) 星野利彦教授が着任しました [Hoshino Toshihiko kyōju ga chakunin shimashita (Professor Toshihiko Hoshino has arrived )]. 3 September: www.cira.kyoto-u.ac.jp/j/pressrelease/other/120903-095145.html [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

CIRM (2016) Proposed strategic plan: 2016 & beyond. California Institute for Regenerative Medicine. 8 December: www.cirm.ca.gov/sites/default/files/files/agenda/151217_Agenda_7_CIRM_StratPlan_final_120815.pdf [3/1/2024].

Clinicaltrials.gov (2013) Search 'Beike Biotech' http://clinicaltrials.gov/ct2/results?term=beike&Search=Search [3/1/2024].

ClinicalTrials.gov (2016) http://clinicaltrials.gov/ct2/show/NCT01440309 [3/1/2024].

CMI (2023) Global regenerative medicine market 2023–2032: www.custommarketinsights.com/report/regenerative-medicine-market/ [3/1/2024].

Coghlan, A. (2010) Death revives warnings about rogue stem cell clinics. *New Scientist, Health*. 17 June: www.newscientist.com/article/dn19056-death-revives-warnings-about-rogue-stem-cell-clinics/?ignored=irrelevant [3/1/2024].

Cohen, E. (2009) *A Body Worth Defending. Immunity, Biopolitics, and the Apothesosis of the Modern Body*. Durham; London: Duke University Press.

Colman, A. (2008) Stem cell research in Singapore, *Cell,* 132: 519–521.

Collins, R. (1968) Competition and social control in science: An essay in theory construction, *Sociology of Education*, 41 (Spring): 123–140.

Cookson, R., Doran, T., Asaria, M., Gupta, I., and Parra Mujica, F. (2021) The inverse care law re-examined: A global perspective, *The Lancet*, 397: 828–838

Cooper, J., Blake, I., and Lindsay, J. O., et al. (2017) Living with Crohn's disease: An exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment, *BMJ Open*, 7: e015201.

Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., et al. (2018) *Lancet* Commission: Stem cells and regenerative medicine, *Lancet*, 391: 883–910.

Cossu, G., Fears, R., Griffin, G., and Ter Meulen, V. (2020) European Academies of Science and Medicine on Regenerative Medicine, *Communication Works*: https://news.cision.com/communication-works/r/european-academies-of-science-and-medicine-on-regenerative-medicine,c3127112 [3/1/2024].

Croley, S. P. (2007) *Regulation and Public Interests*. Princeton: Princeton University Press.

CSN (2018) Cell Surgical Network: https://stemcellrevolution.com/#:~:text=Welcome%20to%20the%20Cell%20Surgical%20Network%C2%AE.,of%20inflammatory%20and%20degenerative%20conditions [3/1/2024].

CURE (2009) Medical Research Council: CURE committee report: www.ukri.org/wp-content/uploads/2021/08/MRC-0208212-CURE-committee-report.pdf [3/1/2024].

Curwen, L. (2020) The risks behind the hype of stem-cell treatments, *BBC News*. 7 January: www.bbc.co.uk/news/health-51006333 [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Cynata Therapeutics (2016) Proactive: Cynata Therapeutics and Japan's Regience K.K. in stem cell alliance: www.proactiveinvestors.co.uk/companies/news/135034/cynata-therapeutics-and-japans-regience-kk-in-stem-cell-alliance-67327.html [3/1/2024].

Cyranoski, D. (2010) FDA challenges stem-cell clinic, *Nature*, 466: 909

(2011) Texas prepared to fight for stem cells, *Nature,* 477, 377–378.

(2012a) China's stem cell rules go unheeded, *Nature*, 484: 149–150.

(2012b) FDA's Claims over stem cells upheld, *Nature*, 488: 14.

(2013a) Controversial stem-cell company moves treatment out of the United States, *Nature*, 30 January.

(2013b) Japan to offer fast-track approval path for stem cell therapies, *Nature Medicine*, 19(5), 510–511.

(2014) Still no stem cells via easy 'STAP' path, *Nature*: https://doi.org/10.1038/nature.2014.16606 [3/1/2024].

Cytori (2015) Japanese approval trial for stress urinary incontinence using Cytori Therapeutics, Inc. cell therapy announced: www.biospace.com/article/releases/japanese-approval-trial-for-stress-urinary-incontinence-using-cytori-therapeutics-inc-cell-therapy-announced-/ [3/1/2024].

(2019) Stem cells 2 go, *Nature,* 573: 482–485.

Cyranoski, D., Sipp, D., Malik, S., and Rasko, J. (2023) Too little too soon: Japan's experiment in regenerative medicine regulation., *Cell Stem Cell,* 30(7): 913–916.

Daley, G. Q., Hyun, I., Apperley, J. F., Barker, R. A., and Benvenisty, N., et al. (2016) Setting global standards for stem cell research and clinical translation: The 2016 ISSCR Guidelines, *Stem Cell Report*, 6: 787–797.

Deane-Drummond, C. (2004) *The Ethics of Nature*. Malden; Oxford; Victoria: Blackwell.

Deinsberger, J., Reisinger, D., and Weber, B. (2020) Global trends in clinical trials involving pluripotent stem cells: A systematic multi-database analysis, *NPJ Regenerative Medicine,* 5: 15.

Demouchel, P. (2015) *The Barren Sacrifice. An Essay on Political Violence*. East Lansing: Michigan State University Press.

(2017) Acting together in dis-harmony: Cooperating to conflict and cooperation in conflict, *Studi di Sociologia*, no. 4: 303–318.

Densford F (2016) MassDevice: www.massdevice.com/avita-medical-eyes-japan-south-korea-for-recell/ [3/1/2024].

Dimitratos, P., and Plakoiyannaki, E. (2003) Theoretical foundations of an international entrepreneurial culture, *Journal of International Entrepreneurship*, 1: 187–215.

Doss, M. X., and Sachinidis, A. (2019) Current challenges of iPSC-based disease modeling and therapeutic implications, *Cells*, 8(5): 403.

Doval, D. C., Shirali, R, and Sinha, R. (2015) Post-trial access to treatment for patients participating in clinical trials, *Perspectives in Clinical Research*, 6(2): 82–85.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Doudement, E. and Uppal, H. (2014) New opportunities for stem cells in drug discovery, *Drug Discovery and Development*. 1 July: https://bit.ly/3H5lYN1 [3/1/2024].

Dulak, J., and Pecyna, M. (2023) Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products, *Stem Cell Reports*, 18(8): 1610–1620.

Dumit, J., (2012a) A digital image of the category of person. In B. J. Good, M. J. Fischer, S. S. Willen and M.-J. DelVecchio Good (eds.) *A Reader in Medical Anthropology: Theoretical Trajectories, Emergent Realities*. Malden, MA: Wiley-Blackwell, 365–376.

(2012b) *Drugs for Life. How Pharmaceutical Companies Define Our Health*. Durham: Duke University Press.

Dupuy, J.-P. (2014) *Economy and the Future*. East Lansing: Michigan State University.

Duster T. Race and reification in science, *Science*, 307:1050–1051.

Dutton G (2007) Stem cell firms struggle for financing, *Gen*. 1 September: www.genengnews.com/gen-articles/stem-cell-firms-struggle-for-financing/2217/ [3/1/2024].

Dzierlega, K., and Yokota, T. (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy, *Gene Therapy*, 27: 407–416.

EBE (European Biopharmaceutical Enterprises) (2011) EBE position paper on the hospital exemption: https://health.ec.europa.eu/system/files/2016-11/07_1_pc_atmp_2013_0.pdf [3/1/2024].

EBISC (2022) European Bank for Induced pluripotent Stem Cells (EBiSC): https://ebisc.org/ [3/1/2024].

Edgington D. (2008) The Japanese innovation system: University-industry linkages, small firms and regional technology clusters, *Promotheus* 26(1): 1–19.

Eguizabal, C., Aran, B., Chuva de Sousa Lopes, S. M., Geens, M., Heindryckx, B., Panula, S., Popovic, M., Vassena, R., and Veiga, A. (2019) Two decades of embryonic stem cells: A historical overview, *Human Reproduction Open*, 1: https://doi.org/10.1093/hropen/hoy024 [3/1/2024].

Ellul, J. (1964) *The Technological Society*. New York: Vintage Books.

EMA (2013) Stem cell therapy treatments. 22 April: www.ema.europa.eu/en/news/stem-cell-therapy-treatments [3/1/2024].

(2014) European Medicines Agency launches adaptive licensing pilot project, 19 March 2014, EMA/430892/2013: https://bit.ly/48GNLPQ [3/1/2024].

(2018) Enhanced early dialogue to facilitate accelerated assessment of PRIority MEdicines (PRIME), EMA/CHMP/57760/2015, Rev. 1. 7 May: www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines [3/1/2024].

(2021) Advanced Therapy Classification: www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/advanced-therapy-classification [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Epstein, S. (1995) The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials, *Science, Technology and Human Values*, 20(4): 408–437.

(1996) *Impure Science: AIDS, Activism and the Politics of Knowledge*. Berkeley: University of California Press.

Eriksson, L., and Webster, A. (2008) Standardizing the unknown: Practicable pluripotency as doable futures, *Science as Culture*, 17(1): 57–69.

Esposito, R. (2011) *Immunitas. The Protection and Negotiation of Life*. Maiden: Polity Press.

Etzkowitz, H., and Leydesdorff, L (2000) The dynamics of innovation: From National Systems and 'Mode 2' to a triple helix of university – industry – government relations, *Research Policy*, 29(2): 109–123.

Eurekalert (2009) Stem cell research: www.eurekalert.org/pub_releases/2009-07/sicp-scr072809.php [3/1/2024].

European Parliament (2007) Regulation (EC) No 1394/2007 of the European Parliament and of the Council. On advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. 13 November: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF [3/1/2024].

(2020) Factsheets on the European Union. The subsidiarity principle: www.europarl.europa.eu/factsheets/en/sheet/7/the-principle-of-subsidiarity [3/1/2024].

Eurostemcell (2022) Explore stem cells: www.eurostemcell.org/stem-cells [3/1/2024].

European Commission (2014) Report from the Commission to the European Parliament and the Council, Brussels, 28 March 2014 COM(2014) 188 final, 7–8: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2014:0188:FIN:EN:PDF [3/1/2024].

EUSPR (2023) European Society for Prevention Research: https://euspr.org/category/featured-projects/ [3/1/2024].

Expresspharma (2020) Stempeutics India and Novumcella Japan to work on development co-operation of Stempeucel product for Japanese market, *Expresspharma*. 1 June: www.expresspharma.in/stempeutics-india-and-novumcella-japan-to-work-on-development-co-operation-of-stempeucel-product-for-japanese-market/ [3/1/2024].

Fanelli D. (2010) Do pressures to publish increase scientists' bias? An empirical support from US States data, *PLoS One*, 5: e10271.

Fantom, N., Fu, H. S., Prince, W. C. (2014) LICs, LMICs, UMICs, and HICs: classifying economies for analytical purposes: https://blogs.worldbank.org/opendata/lics-lmics-umics-and-hics-classifying-economies-analytical-purposes [3/1/2024].

Farmer, P. (2010) *Partner to the Poor: A Paul Farmer Reader*. Edited by H. Saussey. Berkeley: University of California Press.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Faulkner, A. (2012a) Law's performativities: Shaping the emergence of regenerative medicine through European Union legislation, *Social Studies of Science*, 42(5): 753–774.

(2012b) Tissue engineered technologies: Regulatory pharmaceuticalisation in the European Union, *INNOVATION: The European Journal of Social Science Research*, 25 (4) 389–408.

(2019) Special treatment? Flexibilities in the politics of regenerative medicine's gatekeeping regimes in the UK, *Science as Culture*, 28(2): 149–173.

Faulkner, A., and Poort, L. (2017) *Stretching and challenging the boundaries of law: Varieties of knowledge in biotechnologies regulation*, *Minerva* 55(2): 209–228.

Feenberg, A. (1988) Fetishism and form: Erotic and economic disorder in literature. In P. Dumouchel (ed.) *Violence and Truth*. Stanford: Stanford University Press, 134–151.

FIRM (2012) Saisei iryou sangyouka sokushin e no kadai (再生医療産業化促進への課題 [Issues in accelerating the commercialization of regenerative medicine]), presentation by the Forum for Innovative Regenerative Medicine to Cabinet Committee on Regulation and Reform. 29 November: www.cao.go.jp/sasshin/kisei-seido/meeting/2012/togi/life/121129/item2.pdf [3/1/2024].

(2018) The 1st Asia Partnership Conference of Regenerative Medicine Associations, Nihonbashi. 29 April: https://firm.or.jp/apacrm/ [3/1/2024].

Fisher J. A. (2007) Coming soon to a physician near you: Medical neoliberalism and pharmaceutical clinical trials. *Harvard Health Policy Review: A Student Publication of the Harvard Interfaculty Initiative in Health Policy*, 8(1): 61–70.

(2009) *Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials*. New Brunswick, NJ: Rutgers University Press.

Foong, P. (2018) Stemming the tide of unproven autologous stem cell therapies in Australia, *UNSW Law Journal*, no 3: www.unswlawjournal.unsw.edu.au/forum_article/stemming-the-tide-of-unproven-autologous-stem-cell-therapies-in-australia [3/1/2024].

Forda, S., Bergström, R., Chlebus, M., Barker, R., and Høngaard Andersen, P. (2013). Priorities for improving drug research, development and regulation, *Nature Reviews Drug Discovery*, 12: 247–248.

Foucault, M. (2003) *Abnormal: Lectures at the College De France 1974–1975*. Edited by A. I. Davidson. New York: Picador.

Freeman, G., and Swidlicki, P. (2014) The EU impact on the UK life science sector: www.eufreshstart.org/downloads/lifesciences2.pdf.

Freitag, J., Wickham, J., Shah, K., Li, D., Norsworthy, C., and Tenen, A. (2020) Mesenchymal stem cell therapy combined with arthroscopic abrasion arthroplasty regenerates cartilage in patients with severe knee osteoarthritis: A case series, *Regenerative Medicine*, 15(8): 1957–1977.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Fukuyama, F. (2004) The imperative of state building, *Journal of Democracy*, 15(2): 17–31.

Galtung, J. (1969) Violence, peace, and peace research, *Journal of Peace Research*, 6(3): 167–191.

Gardner, J. (2017) Distributive justice and regenerative medicine, *Regenerative Medicine*, 12(7): 865–874.

Gawande, A. (2015) *Being Mortal. Illness, Medicine, and What Matters in the End*. London: Profile Books.

Ghinea, N., Munsie, M., Rudge, C., and Stewart, C. (2020) Australian regulation of autologous human cell and tissue products: Implications for commercial stem cell clinics, *Regenerative Medicine*, 15(2): 1361–1369.

Gieryn, T. (1983) Boundary-work and the demarcation of science from non-science: Strains and interests in professional ideologies of scientists, *American Sociological Review*, 48: 781–795.

Gilbert, N., and Mulkay, M. (1984) *Opening Pandora's Box: A Sociological Analysis of Scientists' Discourse*. Cambridge: Cambridge University Press.

Girard, R. (1986) *The Scapegoat*. Baltimore: John Hopkins University Press.

(2000) Violence Renounced. In W. Swartley (ed.) *Violence Renounced: René Girard, Biblical Studies, and Peacemaking*. Telford, PA: Pandora Press, 308–319.

(2016) *Things Hidden Since the Foundation of the World*. London; New York: Bloomsbury.

(2020 [1977]) *Violence and the Sacred*. Translated by P. Gregory. London; New York: Bloomsbury.

Glass, K. C.(2006) Questions and challenges in the governance of research involving humans: A Canadian perspective. In T. Lemmens and D. Waring (eds.) *Law and Ethics in Biomedical Research: Regulation, Conflict of Interest and Liability*. Toronto: University of Toronto Press, 35–41.

Global News Wire (2015) The Alliance for Regenerative Medicine enters into memorandum of understanding with Japan's Forum for Innovative Regenerative Medicine (Press Release ARM). 12 March: https://bit.ly/3vq8Q2E [3/1/2024].

Görg, C., and Brand, U. (2006) Contested regimes in the international political economy: Global regulation of genetic resources and the internationalization of the State, *Global Environmental Politics*, 6(4): 101–123.

Gottweis, H., Salter, B., and Waldby, C. (2009) *The Global Politics of Human Embryonic Stem Cell Science*. Basingstoke: Palgrave Macmillan.

GSCRMA (2017) 广州干细胞与再生医学联盟 [Guangzhou ganxibao yu zaishengyixue lianmeng (Guangzhou Stem Cell and Regenerative Medicine Alliance)]: www.gibh.cas.cn/ydhz/hzdt/200908/t20090807_2352362.html [3/1/2024].

Guangzhou Shengwu-Yiyaowang (2014) 广州生物医药王 [Guangzhou Shengwu YiyaoWang]: www.gzbio.org/ [16/2/2016].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Gunter, K. C., Caplan, A. L., Mason, C., Salzman, R., Janssen, W.E.,et al. (2010) Cell therapy medical tourism: Time for action (ISCT White Paper) *Cytotherapy*, 12: 965–968: www.isct-cytotherapy.org/article/S1465-3249(10)70464-3/fulltext [3/1/2024].

Guston, D. H. (2000) Retiring the social contract for science, *Issues in Science and Technology,* xvi(4): https://issues.org/p_guston/ [3/1/2024].

Haas, P. (1992) Epistemic communities and international policy coordination, *International Organization*, 46(1): 1–35.

Hagstrom, W. O. (1974) Competition in science, *American Sociological Review*, 39(1): 1–18.

HanShi Lianhe (2011) Health & Biotech: www.health-biotech.com/en/com-news-detail009.html [7/3/2017].

Haraway, D. (2013) The biopolitics of postmodern bodies: Constitutions of Self in immune system discourse. In T. Campbell and A. Sitze (eds.) *Biopolitics: A Reader*. Durham: Duke University Press, 274–309.

Hargreaves, B. (2019) 'Can you manufacture consistently?' The big question in regenerative medicine, *BioPharma*: www.biopharma-reporter.com/Article/2019/03/11/State-of-the-regenerative-medicine-industry [3/1/2024].

Harmon, S., and Kale, D. (2015) Regulating in developing countries: Multiple roles for medical research and products regulation in Argentina and India, *Technology in Society*, 43: 10–22.

Harrington, J., and Hauskeller, C. (2014) Translational research: An imperative shaping the spaces in biomedicine, *TECNOSCIENZA, AnItalian Journal of Science & Technology Studies,* 4(2): 73–91.

Harris, J. (2005) Scientific research is a moral duty, *Journal of Medical Ethics*, 31(4): 242–248.

Haslam, D. (2022) *Side Effects: How our Healthcare Lost Its Way*. London: Atlantic Books.

Hauskeller, C., Baur, N., and Harrington, J. (2017) Standards, harmonization and cultural differences: Implementation of a European stem cell clinical trial, *Science as Culture*, 28(2): 174–199.

Hauskeller, C. (2018) Between the local and the global: Evaluating European regulation of stem cell regenerative medicine, *Perspective in Biology and Medicine*, 61(1): 42–58.

Hayden, E. C. (2014) Activists sound alarm on tiered drug prices, *Nature*, 509: 412.

Herrin, C. (2020) Government health care restrictions are costing lives, *The Hill*. 30 June: https://thehill.com/opinion/healthcare/505257-government-health-care-restrictions-are-costing-lives [3/1/2024].

HHP (2014) Overview of the plan for promotion of medical research and development: www.kantei.go.jp/jp/singi/kenkouiryou/en/pdf/plan.pdf [3/1/2024].

Hills, A., Awigena-Cook, J., Genenz, K., Ostertag, M., Butler, S., Eggimann, A.V., and Hubert, A. (2020) An assessment of the hospital exemption landscape

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

across European Member States: Regulatory frameworks, use and impact, *Cytotherapy*, 22(12): 772–779.e1: www.isct-cytotherapy.org/article/S1465-3249(20)30847-1/fulltext [3/1/2024].

Hishiyama, Y. (2010) *Raifu-Saiensu Seisaku no Genzai* (ライフサイエンス政策の現在 [The Current State of Life-Science Policy]). Tokyo: Keiso Shobo.

HISO (Health Information Systems Office) HISO report: www.hiso.or.th/hiso5/report/download.php?name=eng2010_22 [3/1/2024].

Holbein, M. E. B., Berglund, J. P., Weatherwax, K., Gerber, K. E., and Adamo, J. A. (2015) Access to investigational drugs: FDA expanded access programs or 'right-to-try' legislation?, *Clinical and Translational Science (CTS)*, 8(5): www.ncbi.nlm.nih.gov/pmc/articles/PMC4503515/ [3/1/2024].

Holistic Medical Centre (2022) Holistic Medical Centre: www.holistic-medical.com/ [3/1/2024].

Hong, S. (2008) The Hwang scandal that 'shook the world of science', *East Asian Science, Technology and Society: An International Journal*, 2(1): 1–7.

House of Lords (2013) Science and technology select committee regenerative medicine oral and written evidence: www.parliament.uk/documents/lords-committees/science-technology/RegenerativeMedicine/RegenMed.pdf [3/1/2024].

hPSCReg (2022) About hPSCReg: https://hpscreg.eu/about [3/1/2024].

Huang, H., Young, W., Skaper, S., Chen, L., Moviglia, G., et al. (2019) Clinical neurorestorative therapeutic guidelines for spinal cord injury (IANR/CANR version 2019), *Journal of Orthopedic Translation*, 20: 14–24.

Hunt P., and Khosla, R. (2010) Are drug companies living up to their human rights responsibilities? The perspective of the former United Nations Special Rapporteur (2002–2008), *PLoS Med*, 7(9): e100030: https://doi.org/10.1371/journal.pmed.1000330 [3/1/2024].

Hyun, I. (2010) Allowing innovative stem cell–based therapies outside of clinical trials: Ethical and policy challenges, *Journal of Law, Medicine & Ethics*, Summer: 277–285.

IANR (2021) The International Association for Neurorestoratology: www.ianr.org.cn/ [3/1/2024].

IBRI (2015) 滲出型加齢黄斑変性に対する自家 iPS 細胞由来網膜色素上皮シート移植に関する臨床研究における被験者募集について [Shinshutsu-gata kareiōhanhensei ni taisuru jika iPS saibō yurai mōmaku shikisojōhi shīto ishoku ni kansuru rinshō kenkyū' ni okeru hikensha boshū ni tsuite (Recruitment of subjects for clinical research on autologous iPS cell-derived retinal pigment epithelium sheet transplantation for wet age-related macular degeneration)]: www.riken.jp/pr/news/2013/20130730_1/ [3/1/2024].

ICH (2016) Welcome to the ICH official website: www.ich.org/home.html [03/01/2024]

ICMR-DBT (Indian Council of Medical Research-Department of Biotechnology) (2007) Guidelines for stem cell research and therapy. Director General

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

ICMR, New Delhi: https://main.icmr.nic.in/sites/default/files/guidelines/stem_cell_guidelines_2007_0.pdf [3/1/2024].

ICMR-DBT (Indian Council of Medical Research-Department of Biotechnology) (2013) National guidelines for stem cell research. Director General ICMR, New Delhi: www.ncbs.res.in/sites/default/files/policies/NGSCR%202013.pdf [3/1/2024].

(2017) National guidelines for stem cell research. Director General ICMR, New Delhi: https://dbtindia.gov.in/regulations-guidelines/guidelines/national-guidelines-stem-cell-research-%E2%80%93-2017 [3/1/2024].

ICMS (2013) ICMS guidelines: www.cellmedicinesociety.org/icms-guidelines [3/1/2024].

ICSCN (2014) White Paper: www.stemcellconsortium.org/uploads/documents/Montreal_White_Paper.pdf [10/5/2017].

ICSF (2010) International Stem Cell Forum: https://stemcellforum.org/.

Ida, R. (2002) Ethical questions of the human embryonic stem cells research, *RinshoShinkeigaku [Clinical Neurology]*, 42(11): 1147–1148.

IH (Institute for Hematology) (2014) Institute for Hematology: www.chinablood.com.cn/english/ [10/1/2016].

Intec (2014) 北京英智康复医院 [Beijing Yingzhi kangfu yiyuan (Beijing Yingzhi rehabilitation hospital)]: www.incarehab.com [3/1/2024].

Ioannidis, J. P. (2011) An epidemic of false claims: Competition and conflicts of interest distort too many medical findings, *Scientific American,* 304: 16.

Iijima, H., Isho, T., Kuroki, H., Takahashi, M., and Aoyama, T. (2018) Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: A meta-analysis toward the establishment of effective regenerative rehabilitation, *NPJ Regenerative Medicine*, 3: 15.

Iijima, K., Arai, H., Akishita, M., Endo, T., Ogasawara, K., Kashihara, N., Hayashi, Y. K., Yumura, W., Yokode, M., and Ouchi, Y. (2021) Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan. *Geriatrics, Gerontology, International Journal*, 21(8): 601–613.

Inkwood (2021) Australia and New Zealand stem cell market forecast 2022–2028: https://inkwoodresearch.com/reports/australia-and-new-zealand-stem-cell-market/ [3/1/2024].

Isasi, R., Ginoza, M., Jongsma, K., and Morris, L. (2022) Mending the gaps: Ethically sensitive cells and the evolution of European stem cell policy, *Regenerative Medicine*, 17(8): https://doi.org/10.2217/rme-2022-0043 [3/1/2024].

ISCBI (2010) International Stem Cell Banking Initiative: http://stemcellforum.org/forum_initiatives/international_stem_cell_banking_initiative.cfm.

ISCR (2012) International Stem Cell Registry: www.umassmed.edu/iscr/ [4/3/2019].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

ISCT (2015) Regulatory, quality and operations resources: www.celltherapysociety.org/?page=CommunityResources [4/3/2019].

ISSCR (2008) Guidelines for the clinical translation of stem cells: www.isscr.org/docs/guidelines/isscrglclinicaltrans.pdf [10/5/2023].

(2016) Guidelines for stem cell research and clinical translation: www.isscr.org/docs/default-source/guidelines/isscr-guidelines-for-stem-cell-research-and-clinical-translation.pdf?sfvrsn=2 [10/5/2023].

(2017) Dear Dr. VijayRaghavan: www.isscr.org/docs/default-source/policy-documents/vijayraghavan-letter-final-6617.pdf?sfvrsn=2%20%5Blast%20accessed%20June%202021%5D [8/6/2021].

(2019) ISSCR. Letter Doug Melton: www.isscr.org/docs/default-source/policy-documents/isscr-comments-re-china's-somatic-cell-therapy-rules-20-may-2019.pdf?sfvrsn=2 [8/6/2021].

IWA (2017) Prudent healthcare: A turning point for health and care in Wales: https://bit.ly/48CgbK [3/1/2024].

Jasanoff, S. (2019) *Can Science Make Sense of Life?* Cambridge: Polity Press.

JLT (1948) Medical Practitioner's Act. Act No. 201 of July 30: www.japaneselawtranslation.go.jp/law/detail/?ft=1&re=2&dn=1&x=59&y=13&co=01&ia=03&ja=04&ky=medical+practitioner%5C%27s+act&page=6 [3/1/2024].

JSRM (2015) Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cellsand cell sheet technology, *Regenerative Therapy*, 2: 2–5: www.sciencedirect.com/science/article/pii/S2352320415000255 [3/1/2024].

(2016) Yokohama Declaration: www.linkedin.com/company/jsrm [3/1/2024]

JST (2008)オールジャパン体制の構築に向けた 文部科学省のiPS細胞研究等の推進体制 [Ōrujapan taisei no kōchiku ni muketa bun bukagakushō no iPS saibō kenkyū-tō no suishin taisei (Promotion system for iPS cell research, etc. by the Ministry of Education, Culture, Sports, Science and Technology to build an all-Japan system)]: www.jst.go.jp/keytech/h20-1sanko.pdf [3/1/2024].

JST (2021) Japan Science and Technology Agency (JST). Overview: www.jst.go.jp/EN/about/overview.html [3/1/2024].

JSTA (2015) Research Center Network for Realization of Regenerative Medicine: www.jst.go.jp/saisei-nw/en/ [3/1/2024].

J-Tec (2021) History: www.jpte.co.jp/english/about_us/history.html [3/1/2024].

Johnson, C. (1982) *MITI and the Japanese Economic Miracle: The Growth of Industrial Policy, 1925–1975*. Stanford: Stanford University Press.

Johnson, M. (2010) The cell peddlers – dealing hope to desperate families. *Journal Sentinel*. 1 February: www.jsonline.com/watchdog/watchdogreports/83179987.html [3/1/2024].

Jones, M. V., Wheeler C., and Dimitratos, P. (2011) *International Entrepreneurship in the Life Sciences*. Cheltenham; Northampton: Edward Elgar.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Jordana, J., and Levi-Faur, D. (eds.) (2004), *The Politics of Regulation: Examining Regulatory Institutions and Instruments in the Governance Age*. Cheltenham; Northampton: Edward Elgar.

Jourdan, A. (2016) False hope? China's military hospitals offer illegal experimental cures, *Life*. 11 July: www.reuters.com/article/us-china-hospitals-insight-idUSKCN0ZR0BW [3/1/2024].

Jovic, D., Yu, Y., Wang, D., Wang, K., Li, H., Xu, F., Liu, C., Liu, J., and Luo, Y. (2022) A brief overview of global trends in MSC-based cell therapy, *Stem Cell Review Reports*, 18(5):1525–1545.

Kahn, N. 2015. Regenerative medicine to get boost from deregulation in Japan, *The Japan Times*. 3 September: www.japantimes.co.jp/news/2015/09/03/national/science-health/regenerative-medicine-get-boost-deregulation-japan/#.V0w0tUtLpg0 [3/1/2024].

Kalyvas, S. N. (2019) The landscape of political violence. In E. Chenoweth., et al. (eds.) *The Oxford Handbook of Terrorism*. Oxford: Oxford University Press, 11–33.

Kami, D., Watakabe, K., Yamazaki-Inoue, M., et al. 2013. Large-scale cell production of stem cells for clinical application using the automated cell-processing machine, *BMC Technology*, 13(102): www.biomedcentral.com/1472-6750/13/102 [3/1/2024].

Kanagawa Prefecture (2016) Life innovation in Keihin coastal areas: https://bit.ly/3S3iTDn [3/1/2024].

Kantei (2013) 新たな医療分野の研究開発体制について [Aratana iryō bun'ya no kenkyū kaihatsu taisei ni tsuite (About R & D system in new medical field)]: www.kantei.go.jp/jp/singi/kenkouiryou/suisin/kettei/taisei.pdf [3/1/2024].

Kato, M., and Sleeboom-Faulkner, M. (2018) Motivations for seeking experimental treatment in Japan, *Biosocieties*, 13(1): 255–275.

Kawakami, M., Sipp, D., and Kato, K. (2010) Regulatory impacts on stem cell research in Japan, *Cell Stem Cell*, 6: 415–416.

Kawasaki (undated) Brochure: https://global.kawasaki.com/en/industrial_equipment/medicals/auto_culture/clinical.html [28/5/2018].

(2016) Cells cultured by automation are used for a world-first clinical study in Thailand (press release): https://global.kawasaki.com/en/corp/newsroom/news/detail/?f=20161227_5800 [3/1/2024].

Keating, P., and Cambrosio, A. (2000) Biomedical platforms, *Configurations*, 8(3): 337–387.

(2003) *Biomedical Platforms*. Cambridge, MA: MIT Press.

Keck, M., and Sikkink, K. (1998) *Activists beyond Borders: Advocacy Networks in International Politics*. Ithaca, NY: Cornell University Press.

Kencare (2016) Kencare holdings: www.kencare.com.sg/kencare-holdings [3/1/2024].

Kiatpongsan, S, and Sipp, D. (2008) Offshore stem cell treatments, *Nature Reports Stem Cells*: www.nature.com/articles/stemcells.2008.151 [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Kiatpongsan, S., and Sipp, D. (2009) Monitoring and regulating offshore stem cell treatments, *Science*, 323, 1564–1565.

Kim, B.-H., and Kim, M.-N. (2020) New drug act poses more regulatory setbacks for Korean bio companies, *Pulse*: https://pulsenews.co.kr/view.php?year=2020&no=849881 [3/1/2024].

Kimbrel, E. A., and Lanza, R. (2020) Next-generation stem cells – ushering in a new era of cell-based therapies, *Nature Reviews Drug Discovery*, 19: 463–479.

Kingsbury, B., Malone, D. M., Mertenskötter, P., Stewart, R. B., Streinz, T., and Sunamin, A. (2019) *Megaregulation: Global Economic Ordering after TPP*. Oxford: Oxford University Press.

Kleiderman, E., Boily, A., and Hasilo, C., et al. (2018) Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials, *Stem Cell Research & Therapy*, 9: 307.

Knoepfler, P. S. (2015) Landmark IPSC clinical study on hold due to genomic issue, *The Niche*.1 July: https://ipscell.com/2015/07/firstipscstop/ [3/1/2024].

(2017) The stem cell hard sell: Report from a clinic's patient recruitment seminar, *Stem Cells Translational Medicine*, 6(1): 14–16: https://doi.org/10.5966/sctm.2016-0208 [3/1/2024].

Krimsky, S. (2006) The ethical and legal foundations of scientific 'conflict of interest'. In T. Lemmings and D. W. R. Waring (eds.) *Law and Ethics in Biomedical Research*. Toronto: University of Toronto Press, chapter 4.

Kumamoto University (2011) Shittoku! Nattoku! Duchennegatakinjisutorofii no kokusai kyōdōchiken ni tsuite [in Japanese] (Good to know! On the global clinical trials for Duchenne Muscular Dystrophy), *Kumamoto University Hospital News*, 10: 4.

Kurata, K., and Choi Y.-H. (2012) Dissemination of regenerative medicine in Japan: Promoting commercialization under the regulatory system, *The Research Institute of Economy, Trade and Industry*, January: www.rieti.go.jp/jp/publications/dp/12e004.pdf [3/1/2024].

Lahiry, S., Chaudhury, S., Sinha, R, and Chatterjee, S. (2019) The national guidelines for stem cell research (2017): What academicians need to know?, *Perspectives in Clinical Research*, 10:148–154: www.ncbi.nlm.nih.gov/pmc/articles/PMC6801994/ [3/1/2024].

Lambert, H. (2006) Accounting for EBM: Notions of evidence in medicine, *Social Science and Medicine*, 62: 2633–2645.

Landfeldt, E., Lindgren, P., Bell, C. F., Schmitt, C., Guglieri, M., Straub, V., Lochmüller, H., and Bushby, K. (2014) The burden of Duchenne muscular dystrophy: An international, cross-sectional study, *Neurology*, 83(6): 529–536.

Landzelius, K. (2006) Introduction: Patient organization movements and new metamorphoses in patienthood, *Social Science & Medicine*, 62: 529–537.

Larkin J. (2003) *Strategic Reputation Risk Management*. New York: Palgrave MacMillan.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Latour, B. (1993) *We Have Never Been Modern*. Cambridge, MA: Harvard University Press.

Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., and Caulfield, T. (2008) Stem cell clinics online: The direct-to-consumer portrayal of stem cell medicine, *Cell Stem Cell*, 3: 591–594.

L.A.W. (2015) Overview of the Foreign Contribution Regulation Act in India: www.lexology.com/library/detail.aspx?g=f86ace93-2a47-4ed0-a88a-d54912e1c0e0 [3/1/2024].

Leach, M., Scoones, I., and Wynne, B. (eds.) (2005) *Science and Citizens: Globalization and the Challenge of Engagement, Claiming Citizenship: Rights, Participation and Accountability Series*. London; New York: Zed Books.

Lee, K. M., Han, Y., Yoon, J., Lee, S., and Lee, J. I. (2015) New governmental regulatory system for regenerative medicine in Japan, *Tissue Engineering and Regenerative Medicine*, 12: 167–172.

Lee, T. L., and Lysaght, T. (2017) Adaptive pathways regulations for stem cells: Accelerating access to medicine or deregulating access to markets?, *Scripted*, 14(1): 81–99.

Lemmens, T., and Waring, D. R. (2006) Introduction. In T. Lemmens and D. R. Waring (eds.) *Law and Ethics in Biomedical Research. Regulation, Conflict of Interest and Liability*. Toronto: University of Toronto Press.

Lesyuk, W., Kriza, C., and Kolominsky-Rabas, P. (2018) Cost-of-illness studies in heart failure: A systematic review 2004–2016, *BMC Cardiovasc Disord*, 18: 74: https://doi.org/10.1186/s12872-018-0815-3 [3/1/2024].

Levi-Faur D (2005a) The global diffusion of regulatory capitalism, *Annals of the American Academy of Political and Social Science*, 598(1): 12–32.

(2005b) Regulatory capitalism: The dynamics of change beyond telecoms and electricity, *Governance*, 19(3): 497–525.

(2005c) The global diffusion of regulatory capitalism, *The Annals of the American Academy of Political and Social Science*, 598: 12–32.

Levine, A. D. (2008) Identifying under- and over-performing countries in research related to human embryonic stem cells, *Cell Stem Cell*, 2, 521–524.

Li, Y., Verter, F., Wang, B., and Ning G. (2019) Regulations on cell therapy products in China: A brief history and current status, *Regenerative Medicine*, 14(8): 791–803.

Lim, J.-Y. (2020) Bio firms hope for faster research with 'Cheomsaeng' law in August, *The Korean Herald*. 13 July: www.koreaherald.com/view.php?ud=20200713000831&ACE_SEARCH=1 [3/1/2024].

Lim, L. (2008) Stem-cell therapy in China draws foreign patients: www.npr.org/templates/story/story.php?storyId=88123868 [3/1/2024].

Lindvall, O., and Hyun, I. (2009) Medical innovation versus stem cell tourism, *Science*, 324: 1664–1665.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Lindsay, J. O., Allez, M., Clark, M., Labopin, M., Ricart, E., et al. (2017) Autologous stem-cell transplantation in treatment-refractory Crohn's disease: An analysis of pooled data from the ASTIC trial, *Lancet Gastroenterology Hepatology*, 2(6): 399–406. doi:10.1016/S2468-1253(17)30056-0.

Liu, X., Li, W., Fu, X., and Xu, Y. (2017) The immunogenicity and immune tolerance of pluripotent stem cell derivatives, *Frontiers in Immunology*, 8: https://doi.org/10.3389/fimmu.2017.00645 [3/1/2024].

Locke, J. (2007[1690]) Second treatise of government. In M. Sandel (ed.) *Justice. A Reader*. Oxford: Oxford University Press, 83–126.

Lowdell, M. W., Birchall, M., and Thrasher, A. J. (2012) Use of compassionate case ATMP in preclinical data for clinical trial applications, *Lancet*, 379: 2341.

Lyn, T. E. (2011) China 'stem cell therapies' offer heartbreak to many, Reuters. 21 September: www.reuters.com/article/idUSTRE78K181/ [3/1/2024].

Lysaght, T. (2017) Accelerating regenerative medicine: The Japanese experiment in ethics and regulation, *Regenerative Medicine*, 12(6): 657–668.

Madden, B. (2010) *Free To Choose Medicine: How Faster Access to New Drugs Would Save Countless Lives and End Needless Suffering*. Arlington Heights: The Heartland Institute.

(2017) Free to choose medicine, Powerpoint Presentation. 16 September: https://ssrn.com/abstract=3038163 [3/1/2024].

Madrid, M., Sumen, C., Aivio, S., and Saklayen, N. (2021) Autologous induced pluripotent stem cell–based cell therapies: Promise, progress, and challenges, *Current Protocols,* 1(3): https://doi.org/10.1002/cpz1.88 [3/1/2024].

Magellan Stem Cells (2020) Human stem cells: www.magellanstemcells.com.au/human-stem-cells [6/5/2020].

Mahalatchimy, A., Rial-Sebbag E., Tournay V., and Faulkner A. (2012) The legal landscape for advanced therapies: Material and institutional implementation of European Union rules in France and the United Kingdom, *Journal of Law and Society*, 39: 131–149.

Majone, G. (1994) The rise of the regulatory state in Europe, *West European Politics*, 17(3): 77–101.

(1997) From the positive to the regulatory state: Causes and consequences of changes in the mode of governance, *Journal of Public Policy*, 17(2), 139–167.

Martin, E. (1994) *Flexible Bodies: Tracking Immunity in American Culture from the Days of Polio to the Days of AIDS*. Boston: Beacon Press.

Martinson, B. C., Crain, A. L., Anderson, M. S., and De Vries, R. (2009) Institutions' expectations for researchers' self-funding, federal grant holding, and private industry involvement: Manifold drivers of self-interest and researcher behavior, *Academic Medicine*, 84:1491–1499: doi:10.1097/ACM.0b013e3181bb2ca6 [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Mason, C., and Hoare, M. (2007) Regenerative medicine bioprocessing: Building a conceptual framework based on early studies, *Tissue Engineering*, 13(2): 301–311.

Master, Z., Matthews, K., and Abou-El-Enein, M. (2021) Unproven stem cell interventions: A global public health problem requiring global deliberation, *Stem Cell Reports*, 16(6), 1435–1445: https://doi.org/10.1016/j.stemcr.2021.05.004 [3/1/2024].

Mastroianni, A., and Kahn, J. (2006) Swinging on the pendulum: Shifting views of justice in human subjects research. In T. Lemmens and D. Warinn (eds.) *Law and Ethics in Biomedical Research: Regulation, Conflict of Interest and Liability*. Toronto: University of Toronto Press, 47–60: www.jstor.org/stable/10.3138/9781442676596.7 [3/1/2024].

Mathen, C., and Sinnappah-Kang, N. D. (2020) Stem cell research and therapy in India: General awareness for the public and stem cell therapy providers, *CHRISMED*, 7(2): 90–94: https://journals.lww.com/chri/Fulltext/2020/07020/Stem_Cell_Research_and_Therapy_in_India__General.2.aspx [3/1/2024].

Matoba, S., and Zhang, Y. (2018) Somatic cell nuclear transfer reprogramming: Mechanisms and applications, *Cell Stem Cell*, 23: 471–485.

Matsumura, H., Harunari, N., and Ikeda, H. (2016) First experience using cultured epidermal autografts in Taiwan for burn victims of the Formosa Fun Coast Water Park explosion, as part of Japanese medical assistance, *Burns*, 42(3): 697–703: https://doi.org/10.1016/j.burns.2015.12.009 [3/1/2024].

Matsuyama, A. (2008) 'ヒト幹細胞を用いる臨床研究に関する指針'の概要 ['hito gansaibo o yooiru rinshō kenkyū ni kansuru shosho' no gaiyō (An overview of 'the guideline for clinical research using human stem cells')], 日本臨床 *[Nihon Rinsoō (Japan Clinical)]*, 66(5): 843–849.

McCain, J. (2005) Does race have a place in biotechnological research?, *Biotechnology Healthcare*, 2(6): 54–62.

McCain, K. W. (1991) Communication, competition and secrecy: The production and dissemination of research-related information in genetics, *Science, Technology and Human Value*, 16: 491–516.

McCullough, M. (2008) Stem-cell tourism troubles experts, *Philadelphia Inquirer*. 15 July: www.researchgate.net/publication/228481428_Stem-cell_tourism_troubles_experts [3/1/2024].

McMahon, D. (2014) The global industry for unproven stem cell interventions and stem cell tourism, *Tissue Engineering and Regenerative Medicine*, 11(1): 1–9.

McMahon, D., and Thorsteinsdóttir, H. (2010) Regulations are needed for stem cell tourism: Insights from China, *The American Journal of Bioethics*, 10(5): 34–36.

Meekosha, M., and Soldatic, D. (2014) Human rights discourse and the global South. In D. Soldatic and M. Meekosha (eds.) *The Global Politics of Impairment and Disability*. London; New York: Routledge.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Meldrum (2014) GlobeNewswire Inc: https://bit.ly/3S47lQt [3/1/2024].
Merton, R. K. (1957) Priorities in scientific discovery, *American Sociological Review*, 22: 635–659.
MEXT (2007) iPS Saibou (Jinkō-Tanōsei Kansaibou) Kenkyu nado no kasokuni muketa Sōgō Senryaku [General Strategy to Promote iPS Cell Research]: www.lifescience.mext.go.jp/download/news/ips_senryaku.pdf [3/1/2024].
(2010) 再生医療の実現化プロジェクト（拡充 [Saisei iryō no jitsugen-ka purojekuto (kakujū)] [The Realisation of Regenerative Medicine Project (Extended)]: www.mext.go.jp/a_menu/hyouka/kekka/1289855.htm [3/1/2024].
MFDS (2013) Administrative advance notice for the revision of regulation on review and authorization of biological products (MFDS Notification No. 2013-21, Amended on 5 April) issued on 30 April.
MHRA (2007) Regulation (Ec) No 1394/2007 on advanced therapy medicinal products: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF [3/1/2024].
(2014) Government response to the UK Early Access to Medicines Scheme consultation, March: https://assets.publishing.service.gov.uk/media/6419bd01d3bf7f7ffc14026f/Clinical_Trials_Final_government_response_to_consultation.pdf [3/1/2024].
Minogue, M., and Carino, L. V. (2006) *Regulatory Governance in Development Countries*. Cheltenham: Edward Elgar.
MoH (2003) 人类胚胎干细胞研究的伦理指导原则 [renlei peitai ganxibao yanjiu de lunli zhidao yuanze (Ethical guiding principles on human embryonic stem cell research (No-460), promulgated by the Ministry of Science and Technology and the Ministry of Health, People's Republic of China on December 24)]. www.most.gov.cn/fggw/zfw/zfw/2003/200512/t2005/1214_54948.htm [3/1/2024].
(2009) 卫生部关于印发《医疗技术临床应用管理办法》的通知 [Weishengbu guanyu yinfa yiliao jishu linchuang yingyong guanli banfa de tongzhi (Clinical application of medical technology management approach)]. 16 March, no 18: www.nhc.gov.cn/yzygj/s3585u/200903/1acc529b5b7a440ea0b415cb96b84a86.shtml [3/1/2024].
(2011) 关于开展干细胞临床研究和应用自查自纠工作的通知 [Guanyu kaizhan ganxibao linchuang yanjiu he yingyong zicha zijiu gongzuo de tongzhi (Notification on self-evaluation and self-correction work regarding the development of clinical stem cell clinical research and application)]. 16 December, no 1177: www.nhc.gov.cn/zwgkzt/pkjjy1/201201/53890.shtml [3/1/2024].
(2012) 两家医院违法违规开展干细胞诊疗活动被通报批评 [Liang jia yiyuan weifa weigui kaizhan ganxibao huodong bei tongbao piping (Two hospitals were criticized for carrying out stem cell diagnosis and treatment

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

activities in violation of laws and regulations)]. 13 November: www.gov.cn/jrzg/2012-11/13/content_2264690.htm [3/1/2024].

(2013) 关于征求《干细胞临床试验研究管理办法（试行）》等文件意见的函 [Guanyu chengqiu <ganxibao linchuang shiyan yanjiu guanli banfa (shixing)> deng wenjian yijian de han (Letter regarding soliciting opinions on the 'stem cell clinical trial research management measures (trial)' and other documents)]. 7 March: www.nhc.gov.cn/qjjys/s3581/201501/93647e071ba04d8eafa4ed8fd3ab840a.shtml [3/1/2024].

MoST (2013) 十二五"863"计划生物和医药技术领域"干细胞治疗技术临床转化及应用研究 [Shi-er-wu '863' jihua shenwu he yiyue jishu lingyu 'ganxibao zhiliao jishu linchuanghua ji yingyong yanjiu (The domain of 'stem cell therapy technology and vlinical translation and applied research' of the 12th five year Plan's '863' Program for Biology and Medical Technology)]. 16 February: www.most.gov.cn/kjbgz/201205/t20120507_94184.html [3/1/2024].

Ministry of Commerce [商务部] (2019) 市场准入负面清单（2019年版） [Shìchǎng zhǔn rù fùmiàn qīngdān 2019 niánbǎn (market access negative list, 2019 edition)]: http://tfs.mofcom.gov.cn/article/bc/201911/20191102916059.shtml [3/1/2024].

Ministry of Health and Family Welfare (2019) New drugs and clinical trial rules G.S.R.227 (Hindi/English): https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf [3/1/2024].

Mirowski, P., and Sent E.-M. (2002) Introduction. In P. Mirowski and E.-M. Sent (eds.) *Science Bought and Sold: Essays in the Economics of Science*. Chicago: University of Chicago Press, 1–66.

MoHLW (2006)人ー幹細胞を用いる臨床ー研究に感する指針 [Hito-Kansaibo wo mochiiru rinsyō-kenkyu ni kansuru sishin [Guidelines for clinical research using human stem cells)]. Enacted 1 September: www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000150646.pdf [3/1/2024].

(2015) International Pharmaceutical Regulatory Harmonization Strategy – Regulatory science initiative: www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/150827-01-01.pdf [3/1/2024].

MoH Malaysia (2013) Guidelines for stem cells and therapy – MOH/P/PAK/177.08(GU): www.moh.gov.my/images/gallery/Garispanduan/Stem_Cell/stem_cell_therapy.pdf.

MOJ (2021) Law of the People's Republic of China on Basic Medical Health and Health Care and the Promotion of Health. 26 June: http://en.moj.gov.cn/2021-06/26/c_636455.htm [3/1/2024].

Mol, A. (2002) *The Body Multiple: Ontology in Medical Practice*. Durham: Duke University Press.

Montgomery, C. M. (2012) Protocols and participatory democracy in a north–south product development partnership, *Sociology, Health and Illness*, 34(7): 1053–1069.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

MOPH (2017) Bureau of Drug Control: https://food.fda.moph.go.th/media.php?id=50938252411654144O&name=No.367-(383).pdf [3/1/2024].

MRC (2012) A strategy for UK regenerative medicine: www.ukri.org/wp-content/uploads/2022/02/MRC-020222-AStrategyforUKRegenerativeMedicine.pdf [3/1/2024].

Munsie, M., and Pera, M. (2014) Regulatory loophole enables unproven autologous cell therapies to thrive in Australia, *Stem Cells and Development*, 23(S1): 34–38: www.liebertpub.com/doi/10.1089/scd.2014.0332 [3/1/2024].

Murray, I. R., Chahla, J., Frank, R. M., Piuzzi, N. S., Mandelbaum, B. R., Dragoo, J. L., et al. (2020) Rogue stem cell clinics, *Bone Joint Journal*, 102-B(2): 148–154.

Nakatsuji, N. (2007) Irrational Japanese regulations hinder human embryonic stem cell research, *Nature Reports, Stem Cells*. 9 August: www.nature.com/stem-cells/2007/0708/070809/full/stemcells.2007.66.html [3/1/2024].

Nakatstuji, N. (2015) サイエンスパレット。幹細胞学徒再生医療 [*Saiensu-Paretto. Kansaibōgaku to Saisei Yiryō (Science Palette. Stem Cell Research and Regenerative Medicine)*]. Kyoto: Maruzen.

Nature (2021) Portfolio. Regenerative Medicine: www.nature.com/subjects/regenerative-medicine [3/1/2024].

NEDO (2013) 再生・細胞医療技術および 製造インフラ最適化の研究開発: [Saisei saibō iryō gijutsu wo yo hi ▪ seizō infura saiteki-ka no kenkyū kaihatsu (Research and development of regenerative therapy, technology and the optimization of the manufacturing infrastructure)] www.nedo.go.jp/content/100873753.pdf [3/1/2024].

(2015) NEDO project activities: www.nedo.go.jp/english/introducing_pja.html [3/1/2024].

Nesta (2023) A healthy life: www.nesta.org.uk/healthy-life/?gclid=CjwKCAjw-bkBhB-EiwA4fvKrCNxRcgrZvhU0Oq8aY6mATUZqAtgpoIZlkuD3Fhd9vZyLCT0WvpJwxoCOBwQAvD_BwE [3/1/2024].

Neuralstem (2014) Bioworld Asia: http://neuralstem.com/pharmaceuticals?id=206 [3/1/2024].

NHC (2019) 体细胞治疗临床研究和转化应用管理办法(试行)(征求意见稿)》[Tixibao zhiliao linchuang yanjiu he zhuanhua yingyong guanli banfa (shixing) (Management of clinical research and transformation applications for somatic cell therapy [Draft for Comment])]: www.nhc.gov.cn/wjw/yjzj/201903/01134dee9c5a4661a0b5351bd8a04822.shtml [8/2/2019].

NHMRC (2023) MRFF – 2023 Stem Cell Therapies Grant Opportunity (GO6227): www.nhmrc.gov.au/funding/find-funding/mrff-2023-stem-cell-therapies-grant-opportunity-go6227 [3/1/2024].

NHS (2020) Greener NHS campaign to tackle climate 'health emergency': www.england.nhs.uk/greenernhs/2020/01/greener-nhs-campaign-to-tackle-climate-health-emergency/ [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

NIH (2021) What are clinical trials and studies?: www.nia.nih.gov/health/what-are-clinical-trials-and-studies [3/1/2024].

Nikkei (2014) Japan aims to set global standards for regenerative medicine, *Asian Review*. 7 February: http://asia.nikkei.com/Business/Trends/Japan-aims-to-set-global-standards-for-regenerative-medicine [3/1/2024].

(2016) Japanese companies ramping up regenerative products, *Nikkei*. 3 January: http://asia.nikkei.com/Business/Companies/Japanese-companies-ramping-up-regenerative-products [3/1/2024].

Niscell (2013) Niscell: www.niscell.com/stem-cell-therapy/ [5/1/2016].

(2024) Niscell – collaboration: www.niscell.org/collaboration [3/1/2024].

NIHBT (2011) Overview of current status of stem cell transplantation in Vietnam: www.wbmt.org/wp-content/uploads/2020/05/B1-1_Prof__TRI_T_NG_QUAN_TBG_-_E.pdf [3/1/2024].

NIHN (2022) Health Japan 21: www.nibiohn.go.jp/eiken/kenkounippon21/en/kenkounippon21/mokuhyou.html#Table01 [3/1/2024].

Nishikawa, S., Goldstein, R., and Nierras, C. R. (2008) The promise of human induced pluripotent stem cells for research and therapy, *Nature Reviews Molecular Cell Biology*, 9:725–729.

NMPA (2017)《细胞治疗产品研究与评价技术指导原则》(试行) [Xibao zhiliao chanpin yanjiu yu pinjia jishu zhidao yuance <shixing> (Guiding principles for the research and evaluation of cellular therapy products [trial])] 18 December: www.nmpa.gov.cn/WS04/CL2138/300457.html [8/2/2019].

Nomura, I. (2021) PMDA wa neicha-shi ni kusshita no ka? (in Japanese) (Did PMDA finally give in to Nature?), *Nikkei Medikaru*. 6 October: https://medical.nikkeibp.co.jp/leaf/mem/pub/eye/202110/572229.html [3/1/2024].

Normile, D. (2015) RIKEN announces penalties related to stem cell fiasco. 10 February: www.sciencemag.org/news/2015/02/riken-announces-penalties-related-stem-cell-fiasco [3/1/2024].

(2017) Cutting-edge stem cell therapy proves safe, but will it ever be effective?, *Science*. 15 March: www.sciencemag.org/news/2017/03/cutting-edge-stem-cell-therapy-proves-safe-will-it-ever-be-effective [3/1/2024].

Nussbaum, M. (1986) *The Fragility of Goodness*. Cambridge: Cambridge University Press.

Nwobike, J. (2006) Pharmaceutical corporations and access to drugs in developing countries, *SUR – International Journal on Human Rights*, 4: 127–143.

OECD (2002) Regulatory policies in OECD countries: From interventionism to regulatory governance: https://doi.org/10.1787/9789264177437-en [3/1/2024].

Oh, I. H. (2012) Regulatory issues in stem cell therapeutics in Korea: Efficacy or efficiency?, *Korean Journal of Hematology*, 47: 87–89.

Okura, H., and Matsuyama, Y. (2017) History of development and regulations for regenerative medicines in Japan, *Journal for Stem Cell Research and Therapy*, 7(1): www.longdom.org/open-access/history-of-development-

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

and-regulations-for-regenerative-medicines-in-japan-2157-7633-1000372.pdf [3/1/2024].

Olson (2015) Fringe medical practices in Thailand: www.thailawforum.com/laws/medical-practices-thailand-stem-cell-cloning-cancer-sex-change.pdf [3/1/2024].

Page, S. E. (2006) Path dependence, *Quarterly Journal of Political Science*, 1(1): 87–115: https://web.archive.org/web/20160629130434/http://dev.wcfia.harvard.edu/sites/default/files/Page2006.pdf [3/1/2024].

Pandya, S. (2008) Stem cell transplantation in India: Tall claims, questionable ethics, *Indian Journal of Medical Ethics*, 5(1): 15–17.

Parekkadan, B., and Milwid, J. M. (2010) Mesenchymal stem cells as therapeutics, *Annual Review of Biomedical Engineering*, A15(12): 87–117.

Patra, P. K., and Sleeboom-Faulkner, M. (2009) Bionetworking: Experimental stem cell therapy and patient recruitment in India, *Anthropology & Medicine*, 16(2): 147–163.

(2017) Bionetworking and strategic linking between India and Japan: How clinical stem cell intervention continues despite new regulatory guidelines, *East Asia Journal for Science and Technology Studies, EASTS*, 11(3): 353–372.

PATR Life (2022) PATR Life Clinic @patrlife Beauty, cosmetic & personal care: www.facebook.com/patrlife/ [3/1/2024].

People's Daily (2005) China allows first stem cell injection into clinical test. 2 February: http://english.peopledaily.com.cn/200502/02/eng20050202_172653.html [6/12/2017].

Pérez Velasco, R., Chaikledkaew, U., Myint, C. Y., Khampang, R., Tantivess, S., et al. (2013) Advanced health biotechnologies in Thailand: Redefining policy directions, *Journal of Translational Medicine*, 11(1): www.translational-medicine.com/content/11/1/1 [3/1/2024].

Perrone, M. (2021) US stem cell clinics boomed while FDA paused crackdown, *Science – PBS*. 30 September: www.pbs.org/newshour/science/us-stem-cell-clinics-boomed-while-fda-paused-crackdown [3/1/2024].

Petersen, A., Seear, K., and Munsie, M. (2013) Therapeutic journeys: The hopeful travails of stem cell tourists, *Sociology of Health and Illness*, 36(5): 670–685.

Petersen, A., Munsie, M., Tanner, C., MacGregor, C., and Brophy, J. (2017) *Stem Cell Tourism and the Political Economy of Hope*. Basingstoke: Palgrave MacMillan.

Petryna, A. (2007) Clinical trials offshored: On private sector science and public health, *BioSocieties*, 2(1): 21–40.

(2009) *When Experiments Travel*. Princeton: Princeton University Press.

PFSC (2021) Patients For Stem Cells: https://patientsforstemcells.org/.

Pham, P. (2016) Current status of stem cell transplantation in Vietnam, *Biomedical Research and Therapy*, 3(4): 578-587: www.bmrat.org/index.php/BMRAT/article/view/89 [3/1/2024].

PharmaBiz (2012) Stempeutics to look for tie-ups with global medical device majors for 'Stempeutron'. *PharmaBiz*. 5 April.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Philippidis, A. (2014) Japan moves to regain prominence in biotech, *Gen*. 28 January: www.genengnews.com/insight-and-intelligence/japan-moves-to-regain-prominence-in-biotech/77900022/ [3/1/2024].

(2018) 10 takeover targets of 2018, *Gen*. 26 February: www.genengnews.com/a-lists/10-takeover-targets-of-2018/ [3/1/2024].

Pigeau, G. M., Csaszar, E., and Dulgar-Tulloch, A. (2018) Commercial scale manufacturing of allogeneic cell therapy, *Frontier Medicine*, 5: 233: www.frontiersin.org/articles/10.3389/fmed.2018.00233/full [3/1/2024].

Pittenger, M. F., Discher, D. E., Péault, B. M., et al. (2019) Mesenchymal stem cell perspective: Cell biology to clinical progress, *Regenerative Medicine*, 4: 22.

Pluristem (2016) Pluristem Therapeutics Inc: www.pluristem.com/wp-content/uploads/2016/05/Japan_Approves_Cells_isa.pdf [8/2/2019].

PMDA (2015) PMDA Strategic Plan 2015: www.pmda.go.jp/english/int-activities/outline/0017.html [3/1/2024].

(2016) International Regulatory Forum of Human Cell Therapy and Gene Therapy Products: www.pmda.go.jp/files/000211283.pdf [3/1/2024].

(2017) The Fourth Thailand-Japan Symposium: www.pmda.go.jp/english/symposia/0099.html [3/1/2024].

(2017) Regulation of regenerative medicine in Japan. Presentation by Yoshiaki Murayama: www.pmda.go.jp/files/000219466.pdf [3/1/2024].

(2018) Report of the PMDA-ATC MRCT Seminar 2018: www.pmda.go.jp/english/symposia/0125.html [3/1/2024].

(2021) GCTP適合性調査 [GCTP tekigō-sei chōsa (GCTP Compatibility Survey)]: www.pmda.go.jp/review-services/gmp-qms-gctp/gctp/0002.html [3/1/2024].

(undated) Review reports regenerative medicine products: www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html [3/1/2024].

Polak, T. B., Cucchi, D. G., Darrow, J. J., et al. (2022) Incremental benefits of novel pharmaceuticals in the UK: A cross-sectional analysis of NICE technology appraisals from 2010 to 2020, *BMJ [British Medical Journal] Open*, 12: e058279: https://bmjopen.bmj.com/content/bmjopen/12/4/e058279.full.pdf [3/1/2024].

PRNewswire (2014) Cell line development market by product (equipment, media and reagents): https://bit.ly/41IwrHI [3/1/2024].

Pyre, S. (2012) Dr. Cornelis Kleinbloesem & Cells4health: Scam or stem cell pioneers?, *Stem Cell Therapy Review Journal*. 8 April: https://stemcelltherapyreviewjournal.com/cells4health-dr-cornelis-kleinbloesem-scam-or-stem-cell-pioneers/ [5/1/2021].

Qiu, X., Feng, J. R., Chen, L. P., Liu, S., Zhang, M., et al. (2017) Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: A systematic review and meta-analysis, *Medicine*, 96(26), e7381: https://doi.org/10.1097/MD.0000000000007381 [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

QLifePro (2018) 再生医療の規制調和目指す-アジア初の国際会議開催 [Saisei iryō no kisei chōwa mezasu – ajia-hatsu no kokusai kaigi kaisai (Aiming to Harmonise Regulation for Regenerative Medicine – Inaugural International Conference in Asia)]: www.qlifepro.com/news/20180416/regulated-harmony-of-regenerative-medicine-aim.html [3/1/2024].

Queen Mary University of London (2018) Stem cell transplants to be used in treating Crohn's disease: www.qmul.ac.uk/media/news/2018/smd/stem-cell-transplants-to-be-used-in-treating-crohns-disease.html [3/1/2024].

Rabeharisoa, V. (2006) From representation to mediation: The shaping of collective mobilization on muscular dystrophy in France. *Social Science & Medicine*, 62: 564–576.

Rabeharisoa, V., Moreira, T., and Akrich, M. (2014) Introduction to evidence-based activism: Patients', users' and activists' groups in knowledge society, *BioSocieties*, 9(2): 111–128.

Raffaelli, R. (2018) The principle of subsidiarity, European Parliament 2017, *Fact Sheets on the European Union*: www.europarl.europa.eu/ftu/pdf/en/FTU_1.2.2.pdf [3/1/2024].

Rayment, E. A., and Williams, D. J. (2010) Concise review: Mind the gap: Challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation, *Stem Cells*, 28(5): 996–1004.

Regeneus (2014) Release: https://regeneus.com.au/wp-content/uploads/141126-rgs-new-japanese-laws-take-effect.pdf [3/1/2024].

Remudy (2021) Remudy: www.remudy.jp/ [3/1/2024].

RePricel (2013) Press Release. 28 May: https://bit.ly/4azZVeS [3/1/2024].

Research and Markets (2020) Regenerative medicine markets analysis and forecast, September: www.researchandmarkets.com/reports/5144903/global-regenerative-medicine-market-analysis-and [3/1/2024].

Resnik, D. B., Shamoo, A. E., and Krimsky, S. (2006) Fraudulent human embryonic stem cell research in South Korea: Lessons learned, *Accountability in Research*, 13(1), 101–109.

Richer, S. (2011) Governor Rick Perry puts 'off-label' medical therapy on stage, *Forbes*. 8 August: www.forbes.com/sites/wlf/2011/08/08/governor-rick-perry-puts-off-label-medical-therapy-on-stage/ [3/1/2024].

Robinson, P. G., Murray, I. R., West, C. C., et al. (2019) Reporting of mesenchymal stem cell preparation protocols and composition: A systematic review of the clinical orthopaedic literature, *The American Journal of Sports Medicine*, 47(4): 991–1000.

Rose, N., and Miller, P. (1992) Political power beyond the State: Problematics of government, *The British Journal of Sociology*, 43(2), 173–205.

Rosemann, A. (2013) Medical innovation and national experimental pluralism, *BioSocieties*, 8(1): 58–74.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

(2014a) Why regenerative stem cell medicine progresses slower than expected, *Journal of Cellular Biochemistry* 115: 2073–2076.

(2014b) Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine, *Social Science and Medicine*, 122: 72–80.

Rosemann A., and Sleeboom-Faulkner, M. (2016) New regulation for clinical stem cell research in China: expected impact and challenges for implementation, *Regenerative Medicine*, 11(1): 5–9.

Ratcliffe, E., Glen, K. E., Naing, M. W., and Williams, D. J. (2013) Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: Case studies, *British Medical Bulletin*, 108(1): 73–94.

Saeedi, P., Halabian, R., Fooladi, A. A. I. (2019) A revealing review of mesenchymal stem cells therapy, clinical perspectives and modification strategies, *Stem Cell Investigations*, 6: 34: www.ncbi.nlm.nih.gov/pmc/articles/PMC6789202/ [3/1/2024].

Saengpassa, C., and Sarnsamak, P. (2012) Thai successes in stem-cell research have come despite a lack of funding, *The Nation*. 22 October:www.nationmultimedia.com/national/Show-scientists-the-road-30192788.html [3/3/2015].

Sakai, M. (2014) Patients' commitment in a clinical trial program: Examining Japanese regenerative medicine for spinal cord injuries, *Core Ethics* 10: 97–108.

Salter, B. (2007) State strategies and speculative innovation in regenerative medicine: The global politics of uncertain future, *GBRG Working Papers,* no. 20. July.

(2009) State strategies and the geopolitics of the global knowledge economy: China, India and the case of regenerative medicine, *Geopolitics*, 14(1): 47–78.

Salter, B., and Qiu, R. (2009) Bioethical governance and basic stem cell science: China and the global biomedicine economy, *Science and Public Policy* 36(1): 47–59.

Salter, B, Zhou, Y., and Datta, S. (2015) Hegemony in the marketplace of biomedical innovation: Consumer demand and stem cell science, *Social Science & Medicine*, 131: 156–163.

Scanian, E. (2015) Trial to test stem cells for knee osteoarthritis: www.eurostemcell.org/trial-test-stem-cells-knee-osteoarthritis [3/1/2024].

SCETRA 2016. Message from the president: www.scetra.or.jp/en/union/ [3/1/2024].

Sengoku, S., Mitsuya, S., and Yoshimi, Y. (2015) Regulatory review: Japan's regulatory framework: Seeking to provide impetus to the commercialisation of regenerative medicine products, *Cell & Gene Therapy Insights*: file:///Users/ms284/Downloads/Sengoku1.pdf [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Seyhan, A. A. (2019) Lost in translation: The valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles, *Translational Medicine Communications*, 4, 18: https://doi.org/10.1186/s41231–019-0050-7 [3/1/2024].

Sheldon, T. 2007. The Netherlands ban private stem cell therapy, *British Medical Journal*, 334: 12.

Shakespeare, T. (1993) Disabled people's self-organization: A new social movement?, *Disability and Society*, 8(3): 249–264.

Sharma, A., Gokulchandran, N., Sane, H., and Badhe, P. (2014) *Stem Cell Therapy in Neurological Disorders*. Mumbai: Surekha Press.

Sharma, A., Gokulchandran, N., Sane, H., Badhe, P., and Paranjape, A. (2016) Current global trends in regulations for stem cell therapy and the way ahead for India, *Indian Journal of Stem Cell Therapy*, 2(1): 5–15.

Shizhentang (2014) Shizhentang (in Chinese): www.ganxibaowang.com/ [12/5/2017].

Shrum, W., Joel, G., and Ivan, C. (2007) *Structures of Scientific Collaboration*. Baskerville: MIT Press.

Shrum, W. (2010) Collaborationism. In J. Parker, N. Vermeulen and B. Penders (eds.) *Collaboration in the New Life Sciences*. Farnham; Burlington: Ashgate, 247–258.

Siebers, T. (2011) *Disability Theory*. Ann Arbor: University of Michigan Press.

Singh, M. (2018) India Proposes to Regulate Stem Cells as Drugs; to require clinical trials, licenses: www.indiaspend.com/india-proposes-to-regulate-stem-cells-as-drugs-to-require-clinical-trials-licenses-80799/ [3/1/2024].

Sinostemcells (2015) Sinostemcells: www.sinostemcells.com// [3/1/2024].

Sipp, D. (2009) The rocky road to regulation, *Nature Reports Stem Cells*. 23 September.

(2011) Blog: http://sctmonitor.blogspot.co.uk/2011/01/beike-biotech-under-new-ownership.html [3/1/2024].

(2012) Pay-to-participate funding schemes in human cell and tissue clinical studies, *Regenerative Medicine*, 7(6 Suppl.): 105–111.

(2015) Conditional approval: Japan lowers the bar for regenerative medicine products, *Cell Stem Cell*, 16(4), 353–356.

Sipp, D., and Turner, L.G. (2012) US regulation of stem cells as medical products, *Science*, 338(6112): 1296–1297.

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S., et al. (2017) Marketing of unproven stem cell–based interventions: A call to action, *Science Translational Medicine*, 9(397): 426.

Sipp, D., and Okano, H. (2018) Japan strengthens regenerative medicine oversight, *Cell Stem Cell*, 22(2): 153–156.

Sipp, D., Robey, P. G., and Turner, L. (2018) Clear up this stem-cell mess, *Nature*, 561(7724): 455–457.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Sipp, D., and Sleeboom-Faulkner, M. (2019) Downgrading the regulation of regenerative medicine, *Science*, 365: 644–646.

Sleeboom-Faulkner, M. (2010a) Boundary making and 'good' stem cell research (SCR) in mainland China: Including bioethics, excluding debate, *East Asian Science, Technology and Society: An International Journal*, 4: 31–51.

(2010b) National risk signatures and human embryonic stem cell research in Mainland China, *Health, Risk and Society*, 12(5):491–511.

(2011a) Regulating cell lives in Japan: Avoiding scandal & sticking to nature, *New Genetics and Society*, 3: 227–240.

(2011b) Stem cell research in Asia: Looking beyond formal regulatory exteriors – Introduction, *New Genetics and Society*, 2: 133–137.

(2013) Latent science collaboration: Strategic cultures of bioethical capacity building in Mainland China's stem cell world, *Biosocieties*, 8: 7–24.

(2014) *Global Morality and Life Science Practices in Asia: Assemblages of Life*. Basingstoke; New York: Palgrave MacMillan.

(2016) The large grey area between 'bona fide' and 'rogue' stem cell interventions: Ethical acceptability and the need to include local variability, *Technological Forecasting and Social Change*, 109: 76–86.

(2019) Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine, *Social Studies of Science*, 49: 355–380.

Sleeboom-Faulkner, M., and Patra, P. K. (2011) Experimental stem cell therapy: Biohierarchies and bionetworking in Japan and India, *Social Studies of Science*, 41(5): 696–707.

Sleeboom-Faulkner, M., Chekar, C. K., Faulkner, A., et al. (2016) Comparing national home-keeping and the regulation of translational stem cell applications: An international perspective, *Social Science and Medicine*, 153, 240–249.

Sleeboom-Faulkner M., Chen, H., and Rosemann, A. (2018) Regulatory capacity building and the governance of clinical stem cell research in China, *Science and Public Policy*, 45(3): 416–427.

Slingby, B. T, Nagao, N., and Akabayashi, A. (2004) Administrative legislation in Japan: Guidelines on scientific and ethical standards, *Cambridge Quarterly of Healthcare Ethics*, 13: 245–253.

Smith, R. (2021) Time to assume that health research is fraudulent until proven otherwise?, *BMJ [*British Medical Journal*] Opinion*: https://blogs.bmj.com/bmj/2021/07/05/time-to-assume-that-health-research-is-fraudulent-until-proved-otherwise/ [3/1/2024].

Soares, F., et al. (2014) Investigating the feasibility of scale up and automation of human induced pluripotent stem cells cultured in aggregates in feeder free conditions, *Journal of Biotechnology*, 173: 53–58.

Sohn, J. Y. (2018) Nature Cell's stem cell treatment for Alzheimer's approved in Japan, *Korea Herald*. 20 March: www.koreaherald.com/view.php?ud=20180320000783 [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Sohn, R. L., and Gussoni, E. (2004) Stem cell therapy for muscular dystrophy, *Expert Opinion on Biological Therapy*, 4(1):1–9.

Song, P. (2010) Biotech pilgrims and the transnational quest for stem cell cures, *Medical Anthropology*, 29(4): 384–402.

(2011) The proliferation of stem cell therapies in post-Mao China: Problematizing ethical regulation, *New Genetics and Society*, 30(2): 141–153.

Sousa C. A. (2013) Political violence, collective functioning and health: A review of the literature, *Medical Conflict and Survival*, 29(3): 169–197.

Srinivasan, S. (2006) Rogue research in the guise of stem cell therapy. Infochange Public Health: http://infochangeindia.org/public-health/features/rogue-research-in-the-guise-of-stem-cell-therapy.html [3/2/2017].

Stemcellconsortium (2023) Stemcellconsortium: https://stemcellconsortium.org/ [3/1/2024].

Stem Cell Pioneers (2011) ACMS and AABB announce alliance: https://stemcellpioneers.com/threads/icms-and-aabb-announce-alliance.5092/ [3/1/2024].

StemcellMalaysia (2021) Stem cell therapy: www.cellmalaysia.com/ [3/1/2024].

(2022) StemLife: www.stemlife.com/en/malaysia/corporate_information/history.html [3/1/2024].

Stempeutics (2013) Clinical trials: www.stempeutics.com/clinical_trials.html [8/12/2015].

(2015) Products: Current focus of Stempeutics: www.stempeutics.com/products.html [8/12/ 2015].

Stengers, I. (2018) *Another Science Is Possible: A Manifesto for Slow Science*. Cambridge: Polity Press.

Suda, M. (2015) 捏造の科学者ースタップ細胞事件 [*Netsuzō no Kagakusha – Sutappu Saibō Jiken (Fabricating Scientists: The STAP incident*]. Tokyo: Bungei Shunjukan.

Sui, S., and Sleeboom-Faulkner, M. (2010) Choosing offspring: Case studies of prenatal genetic testing for thalassemia and the reproduction of a 'saviour sibling' in China, *Culture, Health and Sexuality*, 12(2): 167–175.

(2015) Governance of stem cell research and its clinical translation in China, *EASTS*, 9: 1–16.

Sunder Rajan, K (2006) *Biocapital: The Constitution of Postgenomic Life*. Durham: Duke University Press.

Stiglitz, J. (2002) *Globalization and Its Discontents*. London; New York: Penguin Books.

Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, *Cell*, 126: 663–676.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors, *Cell*, 131: 861–872.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Takenaka, T. (2005) Technology licensing and university research in Japan, *International Journal of Intellectual Property*, 1: 27–36.

Tam, F. (2011) Medicine's wild east, *China South Morning Post*. 17 May: www.scmp.com/article/967932/medicines-wild-east [3/1/2024].

Terumo (2015) News room, press release. 18 September: www.terumo.com/pressrelease/detail/20150918/307/index.html [23/4/2019].

TFDA (2017) ASEAN Consultative Committeefor Standards and Quality – Pharmaceutical Product Working Group: www.fda.gov.tw/tc/includes/GetFile.ashx?mID=133&id=66509 [3/1/2024].

TGA (Therapeutic Goods Administration) (2011) Therapeutic goods (things that are not biologicals) determination no. 1: www.legislation.gov.au/Details/F2011L00894 [3/1/2024].

(2015) Products regulated as biologicals: www.tga.gov.au/what-regulated-biological [3/1/2024].

(2019) TGA strengthens regulation of stem cell treatments: https://bit.ly/3S3r0zN [3/1/2024].

Thailand Medical News (2019) Certain clinics in Thailand offering fraudulent stem cell treatment: www.thailandmedical.news/news/certain-clinics-in-thailand-offering-fraudulent-stem-cell-treatments [3/1/2024]

Thanawin (2013) Thanawin holding: http://thanawinholding.com/Thanawin_Holding/News%26Events.html) [3/1/2024].

Thomas R., Chandra, A., Hourd, P., and D. Williams (2008) Cell culture automation and quality engineering: A necessary partnership to develop optimised manufacturing processes for cell-based therapies, *Journal of the Association for Laboratory Automation*, 13(3):152–158.

Thomas, P. T., Rajaram, P., and Nalinia, A. (2014) Family care giving in Duchenne Muscular Dystrophy: Is there a gender difference?, *IOSR Journal of Nursing and Health Science (IOSR-JNHS)*, 3(6): 17–22.

Thompson, C. (2013) *Good Science: The Ethical Choreography of Stem Cell Research*. Cambridge, MA: MIT Press.

Thomson, A. J., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998) Embryonic stem cell lines derived from human blastocysts, *Science*, 282(5391): 1145–1147.

Thomson Reuters (2015) Medicinal product regulation and product liability in Vietnam: Overview: http://us.practicallaw.com/6-518-6504?q=&qp=&qo=&qe= [3/1/2024].

Timmermans, S., and Epstein, S. (2010) A world of standards but not a standard world: Toward a sociology of standards and standardization, *Annual Review of Sociology*, *36*, 69–89.

Timmermans, S., and Tavory, I. (2012) Theory construction in qualitative research: From grounded theory to abductive analysis, *Sociological Theory*, 30: 167–186.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Tiwari, S. S., and Desai, P. N. (2018) Unproven stem cell therapies in India: Regulatory challenges and proposed paths forward, *Cell Stem Cell*, 23: 649–652.

Tiwari, S. S., and Raman, S. (2014) Governing stem cell therapy in India: Regulatory vacuum or jurisdictional ambiguity?, *New Genetics and Society*, 33(4): 413–433.

TMC (Thai Medical Council) (2009) Rules on the observance on medical ethics regarding stem cell transplantation for therapeutic treatment B. E. 2552 [in Thai]: www.tmc.or.th/download/stemcell.pdf [3/1/2024].

Tobita, M., Konomi, K., Torashima, Y., Kimura, K., Taoka, M., and Kaminota, M. (2016) Commentary on Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine, *Regenerative Therapy*, 4: 78–81.

Tsai, T.-H., Ling, T.-Y., Lee, C.-H. (2020) Adoption of regulations for cell therapy development: Linkage between Taiwan and Japan, *Clinical Translation Science*, 13: 1045–1047: https://pubmed.ncbi.nlm.nih.gov/32407601/ [3/1/2024].

Tsuyuki, K., Yano, K., Watanabe, N., Aruga, A., and Yamato, M. (2016) Compassionate use of drugs and medical devices in the United States, the European Union and Japan, *Regenerative Therapy*, 4: 18–26.

Turner, L. G. (2017) ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies, *Regenerative Medicine*, 12(6): 705–719.

(2021) The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions, *Cell Stem Cell*, 28(11): 1891–1895.

Turner, L. G., and Knoepfler, P. (2016) Selling stem cells in the USA: Assessing the direct-to-consumer industry, *Cell Stem Cell*, 19(2): 154–157.

UKRI (2020) UK and Japan award eight regenerative medicine projects: www.ukri.org/news/uk-and-japan-award-eight-regenerative-medicine-projects/ [3/1/2024].

(2022) The role of pro-inflammatory mesenchymal stem cells in rheumatoid arthritis: https://gtr.ukri.org/projects?ref=MR%2FK008862%2F1 [3/1/2024].

Umemura, M. (2011) *The Japanese Pharmaceutical Industry*. London: Routledge.

(2015) Positioning Asia in the Japanese regenerative medicine industry: The case of China and India, *Working Paper*. 31 May: www.kcl.ac.uk/sspp/departments/. . ./research/. . ./Working-Paper-50-(2015).pdf [14/3/2020].

UN (2016) The United Nationals Secretary-General's High-Level Panel on Access to Medicines Report: www.unsgaccessmeds.org/final-report [3/1/2024].

Union Stem Cell (2014) 协和孕妇大学 [XieheYunfu Daxue (University for Pregnant Women)]: www.chinastemcell.com/about-xiehe/xiehe-gravida-college.html [2/1/2017].

US-FDA (2007) 21 CFR Part 1271: Human cells, tissues, and cellular and tissue-based products: www.Accessdata.Fda.Gov/Scripts/Cdrh/Cfdocs/Cfcfr/Cfrsearch.Cfm?Cfrpart=1271&Showfr=1 [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

US-FDA (2012) 21 CFR 312.8: Charging for investigational drugs under an IND: www.govinfo.gov/app/details/CFR-2012-title21-vol5/CFR-2012-title21-vol5-sec312-8 [3/1/2024].

(2014a) Investigational new drug applications: www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/default.htm [3/1/2024].

(2014b) Expedited programs for serious conditions – drugs and biologics: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf [3/1/2024].

(2014c) Fast track, breakthrough therapy, accelerated approval and priority review: www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm [6/5/2023].

(2017a) Same surgical procedure exception under 21 CFR 1271.15 (b): Questions and answers regarding the scope of the exception. 2017: https://bit.ly/47rGHoR [3/1/2024].

(2017b) FDA announces comprehensive regenerative medicine policy framework. 19 November: www.fda.gov/news-events/press-announcements/fda-announces-comprehensive-regenerative-medicine-policy-framework [3/1/2024].

(2019) Statement from FDA Commissioner Scott Gottlieb, MD and Peter Marks, MD, PhD. FDA press announcement, January: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629493.htm [3/1/2024].

VietnamNet (2013) Growing stem cells – a new profitable business in Vietnam: https://vietnamnet.vn/en/growing-stem-cells-a-new-profitable-business-in-vietnam-E71113.html [3/1/2024].

Villa Medica (2020) EV Villa Medica, innovative regenerative medicine: https://ewvillamedica.com/ [3/1/2024].

Vogel, S. K. (1996) *Freer Markets, More Rules. Regulatory Reform in Advanced Industrial Countries*. Ithaca; London: Cornel University Press.

Von Tigerstrom, B. (2015) Revising the regulation of stem cell-based therapies: Critical assessment of potential models, *Food Drug Law Journal*, 70(2): 315–337.

Wade, R. (2003) What strategies are viable for developing countries today? The World Trade Organisation and the shrinking of 'development space', *Review of International Political Economy*, 10(4): 621–644.

Wahlberg, A., Rehmann-Sutter, C., Sleeboom-Faulkner, M., Lu, G., Döring, O., and Cong, Y. (2013) From global bioethics to ethical governance of biomedical research collaborations, *Social Science & Medicine*, 98: 293–300.

Walk Again (2015) HAL® Therapy – current scientific studies: http://walk-again.com/research/ [3/1/2024].

Washington State (2022) AG Ferguson wins $500,000 for individuals impacted by US Stemology's unproven claims that its stem cell injections could treat COVID-19 and other medical conditions. 9 June: www.atg.wa.gov/news/

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

news-releases/ag-ferguson-wins-500000-individuals-impacted-us-stemology-s-unproven-claims-its [3/1/2024].

Waters, T., and Waters, D. (eds.) (2015) *Weber's Rationalism and Modern Society*. Basingstoke; New York: Palgrave MacMillan.

Whatclinic (2022) Whatclinic Malaysia: www.whatclinic.com/oncology/malaysia [3/1/2024].

Wang, J. (2011) 国家干细胞研究指导协调委员会成立 [Guojia ganxibao yanjiu zhidao bandiao weiyuanhui chengli (Establishing the National Stem Cell Leadership and Coordination Committee)]. 21 Octobter: http://news.sciencenet.cn/htmlnews/2011/10/254182.shtm [3/1/2024].

Wangkiat, P. (2015) Ministry eyes stem cell therapy adverts, *Bangkok Post*. 23 February: www.bangkokpost.com/thailand/general/480996/ministry-eyes-stem-cell-therapy-adverts [3/1/2024].

Watanabe, S., Kodama, S., and Hanabusa, H. (2018) Longevity and elderly care: Lessons from Japan, *Global Health Journal*, 2(4): 5–10.

Webster, A. (ed.) (2013) *The Global Dynamics of Regenerative Medicine: A Social Science Critique*. Basingstoke; New York: Palgrave MacMillan.

WHO (2012) Pharmaceutical financing strategies (MSD-3), chapter 11: http://apps.who.int/medicinedocs/documents/s19587en/s19587en.pdf [3/1/2024].

(2017) World Bank and WHO: Half the world lacks access to essential health services, 100 million still pushed into extreme poverty because of health expenses: www.who.int/news/item/13-12-2017-world-bank-and-who-half-the-world-lacks-access-to-essential-health-services-100-million-still-pushed-into-extreme-poverty-because-of-health-expenses [3/1/2024].

(2022) Universal Health Coverage (UHC): www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc) [3/1/2024].

(2023) WHO ambient air quality database, 2022 update: Status report: www.who.int/publications/i/item/9789240047693 [3/1/2024].

Will, C. (2007) The alchemy of clinical trials, *BioSocieties*, 2: 85–99.

Will, C., and Moreira, T. (2010) *Medical Proofs, Social Experiments. Clinical Trials in Shifting Contexts*. Farnham: Ashgate.

Williams, D. J., Thomas, R. J., Hourd, P. C, Chandra, A., Ratcliffe, E., et al. (2012) Precision manufacturing for clinical-quality regenerative medicine. *Philosophical Translations of the Royal Society*. 28 August. doi:10.1098/rsta.2011.0049 [3/1/2024].

Wilson, T. A. (2016) Patient groups oppose Senate Regenerative Medicine Bill Wilson, *Inside CMS*, 19(22): 7–8: www.jstor.org/stable/10.2307/26706144 [3/1/2024].

Windholz, E. L. (2018) *Governing through Regulation: Public Policy, Regulation and the Law*. Abingdon; New York: Routledge.

WMA (2018) World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects: www.wma

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ [3/1/2024].

Wohn, Y. (2012) Korea okays stem cell therapies despite limited peer-reviewed data, *Nature Medicine*, 18, 3, doi:10.1038/nm0312–329a [3/1/2024].

WPI (2020) World Premier International Research Center Initiative: www.jsps.go.jp/english/e-toplevel/ [3/1/2024].

Wu Medical Centre (2014) Wu Medical Centre. Every life, every family, every hope: www.wumedicalcenter.com/ [3/1/2024].

Wu, S. W., Chen, T., Wu, M., Pan, Q., Xuan, Y., Wei, L. Y., Wang, Q., Li, C., and Song, J. C. (2016) Management of medical technology under the new medical policy background in China, *Chinese Medical Journal*, 129(22): 2745–2748: https://doi.org/10.4103/0366-6999.193453 [3/1/2024].

Wu, W., Wang, Y., Tang, Z., Gao, Y., and Huo, Y (2020) Regulatory oversight of cell therapy in China: Government's efforts in patient access and therapeutic innovation, *Pharmacological Research*, 158: www.sciencedirect.com/science/article/pii/S104366182031197X [3/1/2024].

Xie, X., and Ma, M. (2020) Winning in the cell and gene therapies market in China: www2.deloitte.com/content/dam/insights/us/articles/APAC_63550_Winning-in-the-cell-and-gene-therapies/DI_China_CGT_white_paper.pdf [3/1/2024].

Yamakoshi, A. (undated) The changing face of NGOs in Japan: www.gdrc.org/ngo/jpngo-face.html [3/1/2024].

Yamanaka, S. (2020) Perspective – pluripotent stem cell–basedcell therapy: Promise and challenges, *Cell Stem Cell*, 27(1): 523–531: https://pubmed.ncbi.nlm.nih.gov/33007237/ [3/1/2024].

Yamasaki, D., and Arai, S. (2014) Japan's stem-cell therapy progress accelerates, *Asian Review*, 10 March: http://asia.nikkei.com/Tech-Science/Science/Dainippon-Sumitomo-Pharma-expanding-iPSrelated-operations [3/1/2024].

Yang, J. (2007) Serve the people: Communist ideology and professional ethics of medicine in China. PhD dissertation. Sydney: Faculty of Arts and Social Sciences, University of Technology.

Ye, J., Bates, N., Soteriou, D., Grady, L., Edmond, C., et al. (2017) High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos, *Stem Cell Research & Therapy*, 8, 128: https://doi.org/10.1186/s13287–017-0561-y [3/1/2024].

Yin F, Tian Z. M., Liu S., Zhao Q. J., Wang, R. M., Shen L., et al. (2012) Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease, *CNS Neuroscience Therapy*, 18(12): 1012–1020.

Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., Slukvin, I. I., and Thomson, J. A. (2007) Induced pluripotent stem cell lines derived from human somatic cells, *Science*, 318(5858): 1917–1920.

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015

Zhai X.-M., Ng, V., and Lie, R. (2016) No ethical divide between China and the West in human embryo research, *Developing World Bioethics*, 16(2): 116–120: https://doi.org/10/f8wcc4 [3/1/2024].

Zhai, X.-M., Lei, R., Zhu, W., Qiu, R. (2019) Chinese bioethicists respond to the case of He Jiankui, *The Hastings Centre*: www.thehastingscenter.org/chinese-bioethicists-respond-case-jiankui/ [3/1/2024].

Zhang, J. (2012) *The Cosmopolization of Science: Stem Cell Governance in China*. Basingstoke; New York: Palgrave MacMillan.

(2017) Lost in translation? Accountability and governance of clinical stem cell research in China, *Regenerative Medicine*, 12(6): 647–656.

Zhang, J., and Datta-Burton, S. (2021) *The Elephant and the Dragon in Contemporary Life Sciences*. Basingstoke: Palgrave Macmillan.

Zhihu (2021)两会聚焦干细胞|干细胞等技术将在中国得到快速发展，成都或成"国之重器"发展之地(2021) [Lianghui jujiao ganxibao|ganxibao deng jishu jiang zai zhongguo dedao kuaisu fazahan, chengdu huo cheng 'guozhi zhongqi' fazhan zhi di (Two sessions focus on stem cells: Stem cells and other technologies will be developed rapidly in China, and Chengdu may become a place for the development of "the most important tool of the country)]: https://zhuanlan.zhihu.com/p/356039878 [3/1/2024].

Zhongyuan Union (2014) 中源协和细胞基因工程股份有限公司 关于收购深圳市北科生物科技有限公司13%股权的公告 [Zhongyu Xiehe xibao-jiin goncheng gufen youxiancongsi guanyu shogou Shenzhen-Shi Beike Shenwu Keji Youxian Gongsi 13% guquan de gonggao]: http://data.eastmoney.com/notices/detail/600645/AN201412220007970166,JUU0JUI4JUFEJUU2JUJBJTkwJUU1JThEJThGJUU1JTkyJThD.html [3/1/2024].

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 15 Nov 2026 at 02:46:32, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009461757.015